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1Foreword
Foreword
As Chair of the Animals in Science Committee, it is my 
pleasure to introduce this review of the use of harm-benefit 
analysis (HBA) in animal-based research and testing, which 
has been produced by a sub-group of the committee under 
the leadership of Professor Gail Davies. The importance 
of the topic is thrown into sharp relief by a few numbers. 
In 1871 a woman’s life expectancy at birth in England and 
Wales was only 45 years. A century later it stood at 75 
and by 2011 it had reached 83. Many factors contributed 
to this improvement, but progress in medicine and the 
life sciences played a major role and today these sectors 
contribute substantially to Gross Domestic Product growth, 
exports and job-creation across the UK. But if scientific and 
technological progress has benefited health and wealth, 
it has also brought hazards in its train. Newly-synthesised 
molecules may pose risks to health and the environment and 
innovative medicines may prove ineffective or have harmful 
side effects that outweigh any advantages they may bring.
The volume of regulatory testing has thus expanded in 
parallel with research in medicine and the life sciences. 
Both of these research activities rely heavily on the use 
of laboratory animals. Currently, some two million animal 
procedures are performed annually – around a quarter 
of them in regulatory testing – whilst similar numbers are 
accounted for in the breeding of genetically modified 
animals. The use of animals may – given our current 
state of knowledge – be unavoidable, but it comes at 
a price. Some 80% of animal procedures are currently 
assessed as involving suffering and some 6% as involving 
severe suffering.
Animal suffering has long been a matter of concern to 
British public opinion and legislation to protect animals was 
placed on the statute book in Victorian times. Few now 
would condone the killing or mutilation of animals merely 
to entertain spectators, but the use of animals in research 
attracts a wide spectrum of opinion. At one extreme lies 
the belief that our ethical commitment to humanity should 
override any concern for non-human species, whilst at the 
other is the attribution of natural rights to animals which 
would prohibit their use in any procedure on the basis that 
they are unable to give informed consent. The weight of 
public opinion, however, holds the use of animals to be 
acceptable if and only if: the reasonably-foreseeable benefits 
outweigh the welfare costs (or ‘harms’) unavoidably imposed 
on the animals; there is no other way in which these benefits 
can be obtained; and the work is undertaken to the highest 
practicable welfare standards. 
This, essentially utilitarian, HBA calculus is embodied in  
the Animals (Scientific Procedures) Act that governs animal-
based research in the UK. As Professor Davies and her 
colleagues point out, whilst HBA constitutes an essential 
stage in the scrutiny of project licence applications under the 
Act, it does not end here. The HBA should be seen as an 
ongoing process, which continues throughout the life of the 
licence and the work carried out under it. 
Professor Davies’ group have carried out an ambitious 
analysis of the underpinnings and implementation of 
HBA. Much of their work is concerned with the problem 
of animal suffering – particularly that characterised as 
‘severe’ under the Act – and with identifying, endorsing 
and promoting best practice in this respect. They also raise 
questions which have not always received the attention 
they deserve and require to be debated in the context of 
future policy formulation, for instance, how should societal 
concerns attaching to some novel procedures be identified 
and addressed? Of particular interest, however, are the 
questions raised in respect of the hitherto under-examined 
area of allowable ‘benefits’. Should, for example, this 
category be expanded to include public engagement with 
and understanding of, science? How should we weigh the 
proposed benefits of research in basic science which may 
only be fully realised long after the conclusion of the project 
itself? Similarly, in the case of regulatory safety testing 
– which accounts for most of the procedures involving 
‘severe’ suffering – the substances tested are treated equally 
regardless of their nature and purpose (except for those 
such as tobacco products and cosmetics where animal 
testing is forbidden). Is it really appropriate to equate the 
benefits of a new food colouring to those of a potentially life-
saving pharmaceutical?
The importance of the HBA process to the conduct of 
animal-based research and testing cannot be overstated 
and I am grateful to Professor Davies and her colleagues 
for their far-reaching analysis of its bases and their pointers 
to the way forward. These will be of interest to all those 
concerned with this vital issue, on whatever side of the 
debate they may find themselves.
Dr John Landers,  
Chair of the Animals in Science Committee
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4Executive Summary
Executive Summary
This report sets out the Animals in Science 
Committee (ASC) review of the processes of harm-
benefit analysis (HBA) carried out under the UK 
Animals (Scientific Procedures) Act 1986 (A(SP)A). 
The A(SP)A requires the HBA of a programme of 
work to assess whether the harm that would be 
caused to protected animals, in terms of suffering, 
pain, distress and lasting harm, can be justified by 
the expected outcome, taking into account ethical 
considerations and the expected benefit to human 
beings, animals, or the environment. 
The UK Home Office Inspectorate, part of the 
Animals in Science Regulation Unit (ASRU), 
undertakes HBA as part of the evaluation of 
project licence applications to use animals 
in research and testing. ASRU produced an 
Advisory Note (ASRU, 2015) explaining how the 
HBA process is applied to new project licence 
applications. 
This ASC report was subsequently commissioned 
to make recommendations on how current 
arrangements for performing a HBA might be 
improved. It draws on: 
• international policy discussions on HBA 
• recent academic literature on key aspects 
of HBA 
• a review of past project licence applications
• new ASC research on the identification and 
assessment of benefits 
The ASC report concludes that HBA remains a 
legitimate ethical framework for evaluating the use 
of animals in research and testing.
HBA continues to be the cornerstone 
of project licence evaluation, in which a 
decision is made determining if the overall 
harm that will occur is justified by the 
benefits that are likely to be delivered.
HBA continues to be the cornerstone of project 
licence evaluation, in which a decision is made 
determining if the overall harm that will occur 
is justified by the benefits that are likely to be 
delivered. The processes of HBA are also 
important throughout the life of a project. They can 
be used to direct efforts to reduce harms and 
maximise benefits during research. They can also 
help recognise at what point a project, procedure, 
animal ‘model’ or research trajectory can no 
longer be ethically justified. 
However, the operational processes of HBA 
require regular dialogue and ongoing review to 
ensure that they remain robust, effective and 
transparent in realising these objectives. 
The ASC identified the following opportunities to 
enhance the implementation and review of HBA.
• Understandings of harms and benefits 
are not fixed in time. There are novel 
scientific techniques and frameworks to help 
to recognise and mitigate harms, including 
around cumulative and severe severity. 
There are also new mechanisms for evaluating 
research design and research impact, 
which can be used to assess and improve 
the likelihood of benefits.
• There are new resources for learning and 
review. HBA has been primarily thought 
of as a prospective evaluation of the likely 
harms to animals and potential benefits of a 
programme of research. Requirements, since 
2014, to return data on actual severity and the 
growing documentation of research impact are 
enhancing capacities for learning and review. 
• Realising these opportunities requires 
enhanced dialogue. Further improvements 
to the HBA will be supported by increasing 
communication between the different HBA 
processes. This includes engaging with 
changing societal views around how seriously 
certain types of harms are regarded and 
whether some kinds of benefits resulting from 
animal research can be justified.
Following review of these resources and 
opportunities, this report concludes with 
recommendations for improving good practice, 
learning and dialogue across the processes 
of HBA, both in and outside of the regulatory 
framework implemented by the Home Office.
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Glossary
3Rs The replacement, refinement and reduction of the use of animals in research. 
This is the framework for the humane use of animals in scientific research. 
The 3Rs are embedded in national and international legislation regulating the 
use of animals.
ACHM Animals containing human material.
AMS Academy of Medical Sciences, an independent UK learned society representing 
medical science. The mission of the AMS is to advance biomedical and health 
research and translate this into benefits for society. The AMS has conducted 
work on scientific good practice and integrity, including a public dialogue on 
ACHM (see above).
APC Animal Procedures Committee (now replaced by the ASC, see below).
ARRIVE guidelines Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines, 
produced by the NC3Rs in consultation with the scientific community. ARRIVE 
aims to improve the reporting of research using animals – maximising the 
information published and minimising irreproducibility of research. 
ASC Animals in Science Committee, an advisory non-departmental public body 
of the Home Office. The ASC was established by the Animals (Scientific 
Procedures) Act 1986 (see below) to oversee the protection of animals used for 
scientific purposes. The ASC is responsible for providing impartial, balanced 
and objective advice to the Secretary of State, to animal welfare bodies and to 
partners within the European Union.
A(SP)A The Animals (Scientific Procedures) Act 1986. The A(SP)A regulates procedures 
that are carried out on protected animals for scientific or educational purposes 
that may cause pain, suffering, distress or lasting harm. The Act also regulates 
the breeding and supply of certain species of animals for use in regulated 
procedures or for the scientific use of their organs or tissues.
ASRU Animals in Science Regulation Unit, Home Office. ASRU is responsible for 
regulating the operation of the A(SP)A. The activities of ASRU include the 
development of policy, regulation of licensing, inspections and investigations of 
non-compliance. 
AWAG Animal welfare assessment grid. Open source software tool for use in 
implementing a quantitative matrix-based animal welfare assessment system.
AWERB Animal Welfare and Ethical Review Body. AWERBs are required at all 
establishments breeding or using animals for scientific procedures in the UK. 
AWERBs are responsible for the ethical review of new programmes of work, 
amendments to these programmes and the assessment of outcomes.
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Concordat on 
Openness in  
Animal Research
The Concordat was launched by Understanding Animal Research in 
May 2014 and by 2017 had 112 signatories. They have agreed to be more 
open about their use of animals in research and to abide by four commitments 
(Understanding Animal Research, 2014): 
• to be clear about when, how and why they use animals in research 
• to enhance communications with the media and the public about their 
research using animals
• to be proactive in providing opportunities for the public to find out about 
research using animals 
• to report on progress annually and share experiences 
Contingent harms The inherent and inescapable harms arising from the experimental or scientific 
use of an animal. Examples include: 
• being housed in a cage (as opposed to being able to range freely  
in the wild) 
• inability to express a wide range of the natural behaviours 
• handling or transport stress 
• olfactory exposure to a large number of conspecifics (in the case of 
laboratory rodents housed in conventional caging) (ASRU, 2015)
Cumulative effects The ASRU advice note defines cumulative effects as the net impacts of all the 
events (procedurally and husbandry-based) and effects that affect adversely, 
positively and by way of amelioration, the welfare of an animal over its lifetime. 
They include likely habituation, potentiation and/or sensitisation and any 
temporal element in which recovery between events and memory of them and/
or their consequences is likely to be affected.
Cumulative severity The assignment of a severity category in legislation (see below) needs to take 
into account the potential for the intensity, duration, frequency and multiplicity 
of techniques to negatively affect the welfare of an animal over its lifetime ie to 
contribute to cumulative severity. Both the Home Office Inspectorate and the 
EU Directive 2010/63 consider cumulative suffering within a procedure as a key 
issue in assigning severity categories. 
HBA Harm-Benefit Analysis, in which the likely adverse effects (harms to animals) in 
a procedure within a project are weighed against the potential benefits of the 
project for people, animals, or the environment (Home Office, 2014).
HEFCE The Higher Education Funding Council for England. HEFCE funds and regulates 
universities and colleges in England, distributing public money to support 
university research through mechanisms like the REF. 
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Lower threshold The lower threshold of pain caused to an animal in a procedure  
(see Procedure and Severity categories below). 
NC3Rs The National Centre for Replacement, Refinement and Reduction of Animals 
in Research (the 3Rs, see above). The NC3Rs was launched in 2004 to 
increase the focus on the 3Rs across the UK. The NC3Rs funds research 
and early career scientists, supports the development of new technology, 
provides evidence for policy makers and promotes knowledge dissemination 
to the public.
Permissible 
Purposes
Purposes for which a Personal Project Licence (see below) will be granted. 
Purposes include: basic research, translational or applied research, drug 
development, protection of the natural environment, species preservation, 
training and forensic enquiries.
PPL Personal project licence, required for all individuals carrying out procedures 
on animals.
Procedure An act of commission, deliberate omission or permission applied to, or having 
any effect on, an animal (Home Office, 2014). A procedure is regulated if it 
is carried out on a protected animal for a scientific or educational purpose 
and may cause that animal a level of pain, suffering, distress, or lasting harm 
equivalent to, or higher than, that caused by inserting a hypodermic needle 
according to good veterinary practice. This is referred to as the ‘lower threshold’ 
(see Severity categories below).
Project-related 
harms
Harms to animals directly caused by the procedures within a project, compared 
with contingent harms, (see above (ASRU, 2015)).
Protocol A procedure or series of procedures carried out for a particular purpose as part 
of an authorised project.
RCUK Research Councils UK (RCUK) is the strategic partnership of the UK’s seven 
Research Councils. Research Councils distribute public funds to research 
projects across the full spectrum of academic disciplines, from the medical and 
biological science to the arts and humanities, informed by peer review.
REF The Research Excellence Framework (REF) is the system for assessing 
the quality of research in UK higher education institutions. It is run by HEFCE 
and partner bodies in Scotland, Wales and Northern Ireland, every six to seven 
years. The results of the 2014 REF were published in December 2014.
Severity The intensity of pain, suffering, distress or lasting harm experienced by an 
animal during a procedure.
Glossary
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Severity  
categories
There are five levels of severity used to classify harms caused by scientific 
procedures:
• sub-threshold – procedures that are not regulated, because their severity is 
below the ‘lower threshold’ – see Procedures above for further explanation
• non-recovery – procedures that are performed entirely under general 
anaesthesia from which the animal shall not recover consciousness
• mild – procedures that are likely to cause animals to experience short-term 
mild pain, suffering or distress, as well as procedures with no significant 
impairment of the well-being or general condition of the animals
• moderate – procedures that are likely to cause animals to experience 
short-term moderate pain, suffering or distress, or long-lasting mild pain, 
suffering or distress, as well as procedures that are likely to cause moderate 
impairment of the well-being or general condition of the animals
• severe – procedures that are likely to cause animals to experience severe 
pain, suffering or distress, or long-lasting moderate pain, suffering or 
distress, as well as procedures that are likely to cause severe impairment 
(Home Office, 2014)
Severity 
classification
The process of assigning a severity category to a protocol. It may be sub-
threshold, non-recovery, mild, moderate, or severe (see ‘Severity categories’ 
above). It is based upon the greatest degree of pain, suffering, distress, 
or lasting harm likely to be experienced by any animal within that protocol 
after applying all appropriate refinement techniques (Home Office, 2014).
Severity limit The highest level of pain, suffering, distress, or lasting harm that may be 
experienced by any animal undergoing an authorised procedure (or series of 
procedures). It should normally be expressed as a humane end-point in relation 
to an adverse effect that may be expected to occur. Hence a procedure may 
have a number of severity limits, which apply at different times in relation to 
different adverse effects (Home Office, 2014).
INTRODUCTION
CHAPTER 1
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1. Introduction
1.1. ANIMALS IN SCIENCE 
COMMITTEE HARM-BENEFIT 
REVIEW
The Animals (Scientific Procedures) Act 1986 
(A(SP)A) requires a harm-benefit analysis (HBA) of 
a programme of scientific work to assess whether 
the harm that is caused to protected animals in 
terms of suffering, pain and distress is justified 
by the expected outcomes, taking into account 
ethical considerations and the expected benefit 
to human beings, animals, or the environment.
This review of HBAs in the use of animals in 
research was carried out in response to the 
commissioning letter received from the then 
Home Office Minister, Norman Baker, in August 
2014 (see Appendix A). The letter asked the 
Animals in Science Committee (ASC) for advice 
on the current arrangements for performing a 
HBA and consideration of whether these might 
be improved. It also asked the ASC to produce 
advice that particularly considers the most severe 
procedures and, relevant to particular types or 
values of benefit, assist in determining where the 
level of harm lies above which licences should not 
be approved. 
The Animals in Science Regulation Unit (ASRU) 
Inspectorate has undertaken HBA as part of 
the evaluation of project licence applications 
to use animals in research and testing since 
A(SP)A was implemented in 1987. Following 
transposition of the European Directive 2010/63/
EU in 2013, ASRU has produced a series of 
advisory notes, including a document explaining 
how the HBA process is applied operationally to 
new project licence applications (ASRU, 2015). 
This supplements guidance on HBA of project 
licence applications within the Home Office 
guidance (Home Office, 2014, see Appendix I) and 
draws upon the European Commission’s working 
document on project evaluation and retrospective 
assessment (European Commission, 2013).
The HBA advice note (ASRU, 2015) aims to show 
in detail how Home Office inspectors carry out 
HBAs during the evaluation of project licence 
applications and how the outcomes of these 
analyses are used to determine whether a project 
licence will be granted or refused. The focus 
is on how new project licence applications are 
evaluated. It is acknowledged that HBA should 
not be viewed as a one-off event and should be 
appropriately reviewed throughout every licence. 
HBA should not be viewed as a one-
off event and should be appropriately 
reviewed throughout every licence. 
The ASRU advice note has been placed in the 
public domain to advise practitioners and assist 
public understanding of how animal research is 
regulated, in line with the government’s policy on 
openness and transparency. 
This ASC review provides reflection and additional 
comment on this advice note. It draws on 
academic and policy reviews of the processes 
of HBAs, as well as new research on the 
identification and assessment of harms and 
benefits, in order to make recommendations on 
how current arrangements for performing a HBA 
might be improved.
1.2. MEMBERS AND METHODS
The ASC Harm-Benefit Analysis subgroup 
was established in autumn 2014. Its members 
are: Professor Gail Davies (ASC, Chair of the 
subgroup); Huw Golledge (ASC); Penny Hawkins 
(ASC); Anna Rowland (ASC); Sarah Wolfensohn 
(ASC); Jane Smith (Boyd Group, advice and 
report drafting); and Dominic Wells (Animals in 
Science Group at the Royal Society of Biology, 
advisory input). 
Advice, input and access to past project licences 
was provided by members of ASRU. Gabrielle 
King contributed to research on the evaluation of 
benefits at the University of Exeter. The subgroup 
was generously supported throughout their work 
by Dr Jo Wallace and Caroline Wheeler from the 
Home Office Science Secretariat.
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This review aims to encompass all the  
stages of assessing and weighing harms and 
benefits in HBA. These can be summarised  
as three key steps: 
• decision – developing and approving the 
project licence application
• implementation – reducing harms and 
maximising benefits throughout the life of the 
project licence
• reflection – recognising when a project or 
procedure can no longer be justified
Work on harms completed by members  
of the ASC includes:
• consideration of factors involved in the 
assessment of harms, including contingent 
effects relating to husbandry, care and 
transportation practices
• review of recent academic work on identifying 
and assessing cumulative effects
• discussion within the ASC of routes towards 
reducing the use of severe procedures and
• reflection on societal concerns relating to 
harms and how they might affect the HBA
Work on benefits completed by members of 
the ASC includes:
• consideration of current advice on assessing 
and weighing benefits, informed by the HBA 
advice note (ASRU, 2015) and ASC discussion
• interviews with scientists and inspectors 
about how the assessment of benefits 
might be improved
• analysis of relevant impact case studies 
from the 2014 Research Excellence 
Framework, which documents the impact of 
animal research in higher education institutions 
(see methods in Appendix D)
• discussion of findings and recommendations 
from this research at meetings with the ASC, 
ASRU and Higher Education Funding Council 
for England (HEFCE)
The final report was considered and approved 
by the ASC in summer 2017 and a small working 
group set up to inform the implementation of 
recommendations with further assistance from 
members of ASRU.
1.3. SCOPE AND AIMS 
OF THE REPORT
The ASC review seeks to contribute to an ongoing 
and open dialogue around the development of 
HBA in animal research and testing. Robust HBA 
depends on the availability and application of: 
• current evidence for harms to animals 
• current evidence for potential benefits 
• a process of evaluation that is legitimate, 
effective, accountable, transparent and 
inclusive of a variety of perspectives, 
including societal concerns
The review draws on progress in the assessment 
of harms and benefits to make specific 
recommendations for improvements to these 
aspects of the HBA. These recommendations aim 
to ensure processes of HBA are responsive to new 
data and changing societal concerns. The review 
also explores how new techniques, sharing good 
practice and increasing transparency might be 
used to improve decision-making and further 
development of a well-informed, well-judged and 
inclusive HBA. 
The ASC recognises that HBA is situated 
at the heart of regulations on the use of 
animals in research and testing and represents 
an ethical dilemma that cannot be fully 
resolved. For this reason, HBA must be an 
ongoing, dynamic process that is responsive 
to developments in regulatory, scientific, 
societal and animal welfare domains. 
HBA must be an ongoing, dynamic process 
that is responsive to developments in 
regulatory, scientific, societal and animal 
welfare domains. 
The outcomes of HBA will be provisional 
judgements that are likely to change over time,  
as new ways of thinking and working evolve.
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The ASC considers carefully the Minster’s request 
for advice on a level of harm, above which licences 
should not be approved. For this reason, the ASC 
reviews in detail: 
• measures to assess and reduce cumulative 
severity
• triggers for additional scrutiny around severe 
procedures 
• moves to eliminate severe suffering 
• processes used to identify societal concerns 
in the HBA 
However, the ASC does not specify a level of 
harm above which licences should not be granted. 
It notes that recent experience has seen issues 
move from additional scrutiny, formal review and 
subsequent exclusion through the application 
of HBA (for example, the use of great apes, 
testing for cosmetics and household products). 
The ASC suggests that a static cut-off is not 
helpful; weighing harms and benefits will always 
require people to make judgements informed by 
current science and societal concerns. However, 
the ASC does identify additional opportunities 
for transparency, dialogue and learning that could 
be used to enhance HBA processes around this 
issue in the future.
This report is aimed at anyone with an interest 
in the use of animals in scientific procedures, 
both nationally and internationally. This includes 
those who regulate, influence and implement 
HBAs locally, nationally and internationally, 
Members of Parliament and relevant committees 
and, importantly, members of the public.
The specific recommendations to the Minister 
from the ASC on how current arrangements 
for performing a HBA might be improved will 
be published as a separate short advice note 
written with members of ASRU. This advice note 
will draw on the principles and opportunities 
identified in this report, to enable the prioritisation, 
implementation and evaluation of these 
recommendations within ASRU.
REVIEWING  
HARM-BENEFIT 
ANALYSIS
CHAPTER 2
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2. Reviewing Harm-Benefit Analysis
2.1. RECENT DEVELOPMENTS
The Animal Procedures Committee (APC) 
Review of Cost-Benefit Assessment in the 
Use of Animals in Research (APC, 2003) laid 
out the ethical basis for the HBA. It drew on 
consultation with stakeholders to explore how 
such processes were being understood and 
used. Many respondents to this consultation 
believed that HBA had contributed to animal 
welfare, but many were also uncertain how the 
assessment operated in practice. The APC review 
explained the decision-making framework for 
HBA and set out suggestions for ‘moving thinking 
on’. It was a valuable summation and discussion 
document and remains an important resource for 
understanding the ethical principles of HBA on 
which the Animals in Science Committee (ASC), 
the successor to the APC, seeks to build. 
Since the 2003 APC review, there have been 
significant changes in the regulation of animal 
use. The term ‘cost’ has been replaced by 
‘harm’, which is regarded as more descriptive 
of the core ethical issues and less likely to be 
misinterpreted. Both the European Directive 
2010/63/EU (European Commission, 2010) and 
UK legislation regulating animal procedures have 
been revised (Animals (Scientific Procedures) 
Act, 1985, revised≈2013), with the production of 
new guidelines, revised codes of practice and 
amended bodies for delivering HBAs. 
The ASRU remains the key regulatory body 
for HBA and, as noted in Section 1.1, recently 
published an account of “the current processes 
used by the Home Office to conduct a harm-
benefit analysis during the evaluation of a project 
licence application” (ASRU, 2015). However, the 
Ethical Review Process (ERP) has become the 
Animal Welfare and Ethical Review Body (AWERB) 
and the independent government scrutiny 
provided by the APC has been replaced by 
the ASC. 
Many international organisations now require 
animal research to comply with agreed ethical 
principles that include HBA. The need to perform 
an HBA is reflected in legislation and guidelines 
produced for: 
• animal research carried out in Europe under the 
Directive 2010/63/EU (European Commission, 
2013)
• the Office International des Epizooties (OIE) 
Terrestrial Animal Health Code (OIE, 2016, 
Chapter 7.8)
• the Council for International Organizations 
of Medical Sciences and the International 
Council for Laboratory Animal Science (CIOMS-
ICLAS, 2012) 
Since the 2003 review, there have also been 
changes in the recognition of the causes of animal 
suffering and developments in the assessment 
of benefits. Research around animal suffering 
and well-being has been significantly expanded 
from a focus on procedures in the original 
HBA to encompass the impact of housing and 
animal care, as well as the effects of cumulative 
procedures on the life-time experience of animals.
The requirement to record actual levels of animal 
suffering since 2014 offers the potential to 
develop retrospective reviews of HBAs and make 
prospective assessments more accurate. 
The requirement to record actual levels 
of animal suffering since 2014 offers 
the potential to develop retrospective 
reviews of HBAs and make prospective 
assessments more accurate.
In addition, a growing ‘impact agenda’ in 
science and increasingly critical questions around 
experimental design, reproducibility and rigour 
in science have resulted in more research on 
how the benefits from animal research may 
be enhanced. 
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There have additionally been significant moves 
towards public openness with respect to animal 
research and testing, alongside movements 
towards open science. Many academic and 
commercial establishments and other bodies, 
have signed up to the Concordat on Openness 
on Animal Research (Understanding Animal 
Research, 2014). ASRU is making more 
information about the scope and scale of 
regulation on the use of animals in research 
available to the public. In addition to annual 
reports on species and procedures, ASRU 
provides information on non-compliance issues 
and the actual severity of procedures being 
reported. There are also growing moves to make 
data derived from animal research more widely 
accessible through initiatives in open science, 
open data and data sharing. There are proposals 
by some non-governmental organisations that 
increasing openness could and should be 
matched by further democratic input into the 
weighing of these harms and benefits in HBA 
(Lyons, 2014). 
This report from the ASC is thus part of an 
evolving process of developing and reviewing HBA 
(see also Brønstad et al., 2016; Laber et al., 2016). 
It builds on the clarification of ethical frameworks 
by the APC (2003), indicating how subsequent 
developments in scientific knowledge and 
practice, changing societal concerns and growing 
expectations of transparency in regulation may 
offer further opportunities to enhance the HBA. 
Subsequent developments in scientific 
knowledge and practice, changing societal 
concerns and growing expectations of 
transparency in regulation may offer further 
opportunities to enhance the HBA.
2.2. ETHICAL FRAMEWORKS 
HBA in the UK operates as a set of interlocking 
social and ethical frameworks. It requires decision-
making based on utilitarian principles, but also 
includes limits to experimentation on animals 
through recognition of some intrinsic animal rights.
It is implemented in a regulatory context that 
considers the importance of a culture of care, 
requires diligence from everyone involved to 
operate effectively and engages a range of 
wider societal concerns.
It is implemented in a regulatory context 
that considers the importance of a culture 
of care, requires diligence from everyone 
involved to operate effectively and engages 
a range of wider societal concerns.
This relationship between different ethical 
frameworks can be considered a strength of 
HBA as it operates in the UK context. It may be 
one reason the framework has proved enduring 
and adaptable over time. However, it also gives 
rise to complexities, particularly around limits, as 
divergent ethical reasoning and societal concerns 
may be mobilised in assessing applications and 
making judgements about when licences should 
not be approved. These different elements are 
outlined as follows.
• Utilitarian ethics: HBA is a form of decision-
making that uses moral reasoning based on 
utilitarianism; i.e. aiming for the maximum 
balance of benefits over harms for all 
affected. The application of HBA to animal 
research makes two further moral assumptions: 
that animals have moral status given their 
capacity for suffering and that potential harms 
and benefits can be legitimately ‘traded-off’, 
such that greater harms to animals can be 
justified by greater benefits from research. 
• Deontological ethics: There are significant 
exceptions to any expectation that all harms 
and benefits can be traded off in the use 
of HBA in UK animal research and testing. 
Research that involves certain types of 
harms and benefits is now widely agreed to 
be intrinsically wrong. There are effective 
restrictions on the use of certain species and 
the generation of certain types of harm. For 
example, the use of great apes in the UK has 
been forbidden since 1998 and no great apes 
have been used in the UK since at least 1987 
when the UK Animals (Scientific Procedures) 
Act 1986 (A(SP)A) was implemented. Causing 
animals to experience severe pain, suffering 
and distress, which is likely to be long-lasting 
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and cannot be ameliorated, is not normally 
permitted under the A(SP)A. In addition, there 
are certain kinds of benefits that are no longer 
considered acceptable, regardless of the 
levels of harm, such as policy bans on the use 
of animals in testing cosmetics products and 
ingredients and in tobacco and alcohol product 
development. 
• Ethics of care: In the UK, HBA also operates 
within a regulatory framework that requires 
the application of the 3Rs (the replacement, 
refinement and reduction of the use of animals 
in research), incorporating legal commitments 
to mitigate harm to animals, independent of 
benefits. Regulation operates through seeking 
to facilitate local cultures of care that enhances 
the welfare of research animals and supports 
staff who provide care for animals.
• Virtue ethics: Finally, the APC (2003) review 
notes that the quality of judgements relevant to 
HBA also depends largely on the diligence of 
those who make them and their understanding 
and awareness of the issues. Much thus 
rests on the integrity of those involved across 
HBA processes and how conscientiously 
they assume these responsibilities and make 
judgements in practice. 
This combination of ethical frameworks can foster 
a robust and flexible process, but it also produces 
tensions and practical complexities, notably 
concerning the distribution of responsibilities 
within the different stages of HBA and the wider 
processes for identifying limits. These require 
regular review, both inside and outside of the HBA 
undertaken by ASRU, as part of processes for 
continuing improvement of HBA. 
2.3. SOCIETAL CONCERNS
There is a further requirement to engage a 
wide range of perspectives in relation to the 
incorporation of societal or social concerns 
in HBA. “Important animal welfare or ethical 
concerns, novel or contentious issues, or societal 
concerns” are mentioned several times in the 
guidance on A(SP)A (Home Office, 2014) and 
are also listed as criteria for deciding whether 
retrospective assessments will be required (ibid, 
Section 5.17). Criteria for determining whether 
a licence application should be referred to the 
ASC includes “projects of any kind raising novel 
or contentious issues, or giving rise to serious 
societal concerns” (Section 13.5). This includes 
animals containing human material (ACHM) 
(Section 5.18.2), which “may raise significant ethical 
issues and societal concerns”. 
The social concerns associated with animal 
research are varied and may develop with respect 
to a range of issues such as animal welfare, the 
use of genetically modified organisms in food 
production, climate change and trade liberalisation 
(Tothova, 2009; Batie and Schweikhardt, 2010). 
Concerns also differ across society and species 
(Ormandy and Schuppli, 2014) and vary with 
geography. They can both reflect deeply held 
ethical positions and be expressed in ways 
that vary according to the kinds of animal use 
proposed and the methods used to elicit public 
views. Societal concerns around animals are 
important, but these complexities mean they can 
be a challenge to incorporate into HBA. Societal 
concerns are often left undefined in legislation and 
the processes for engaging them left open in the 
guidance or advisory note on HBA (Home Office, 
2014; ASRU, 2015).
In his 2016 Paget Lecture, Mark Walport suggests 
that animal research presents challenges for 
both science and democracy. Its “complexity 
means that animal research is a topic where the 
institutions of science meet the institutions of 
democracy fairly and squarely. It is an area where 
the arguments will continue and the opposing 
cases will need to be made and remade. We live in 
a plural democratic society, where different citizens 
hold different views based on differing moral 
precepts.” This complexity and plurality means that 
many questions around animal research are highly 
resistant to resolution and some arguments maybe 
never be resolved. Nevertheless, he concludes 
“it is for democratic governments to decide on the 
acceptability and conditions under which research 
on animals is undertaken” (Walport, 2016).
There is a significant policy literature on how to 
address these challenges across both science 
and democracy, from the identification of so-called 
“wicked problems” for policy (Rittel and Webber, 
1973) to work on post-normal science (Funtowicz 
and Ravetz, 1993). The policy arenas considered 
and terminology used varies in this research, 
with discussion across planning, economics and 
healthcare. However, all agree that policy issues 
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characterised by complex systems, scientific 
uncertainty and plural values should not be treated 
in the same way as policy questions typified by 
low uncertainty and low conflict.
Instead, what is emphasised across these 
approaches is the importance of acknowledging 
complexity, engaging widely and working 
collaboratively to understand the implications of 
different solutions. For example, in its public policy 
perspective paper, the Australian government 
supports the Organisation for Economic Co-
operation and Development (OECD) approach of 
creating shared understanding about such matters 
by promoting stakeholder and citizen engagement, 
including providing information and facilitating 
active engagement (Australian government, 2012).
Applying such approaches to understand and 
engage societal concerns around animal use may 
have the potential to improve the implementation 
of HBA and allow this to reflect shifts in prevailing 
public opinion and societal concerns. 
Applying such approaches to understand 
and engage societal concerns around 
animal use may have the potential to 
improve the implementation of HBA and 
allow this to reflect shifts in prevailing public 
opinion and societal concerns. 
2.4. ITERATIVE PROCESSES 
HBA has long been a cornerstone for ethical 
evaluation of animal research in the UK, forming 
the basis of the prospective assessment 
framework for evaluation of project licence 
applications. The HBA advisory note (ASRU, 2015) 
is one of the most comprehensive explanations 
of the way HBA is implemented in a regulatory 
context. This document:
• divides the implementation of HBA into a 
sequence of assessments
• provides details of how Home Office inspectors 
identify and weight harms and benefits
• provides details how they weigh the benefits 
against the harms 
These steps are brought together in a flowchart 
(see Appendix B) to illustrate ASRU’s perspective 
on the sequence of events in the HBA. ASRU’s 
flowchart is largely linear, representing its route for 
assessing project licence applications. It does not 
emphasise HBA processes in other contexts or 
before and after the ASRU HBA. Some of these 
additional elements are provided by ASRU itself. 
Ongoing reviews of HBA are offered through 
inspection, notifications required in standard 
conditions for project licences (Home Office, 2014) 
and assessment of project licence amendments. 
These all have the potential to contribute to the 
development of HBA as a continuous process.
However, it is important to recognise that the 
HBA conducted by ASRU is not the only one 
applied to a project. Harms and benefits should be 
carefully considered by the researchers, the local 
establishment AWERB and by referral to the ASC 
if the project has certain features (see Appendix 
C), in addition to the Home Office Inspectorate.
In this report, the ASC seeks to place the HBA 
advice note (ASRU, 2015) on the formal regulatory 
processes of HBA (ASRU, 2015) within the wider 
context of advice, informal discussions and 
feedback that inform it. The operation of and 
relations between different processes of HBAs 
was identified as a priority for further research 
in a recent exercise developing a collaborative 
agenda for humanities and social scientific 
research on laboratory animal science and welfare 
(Davies et al., 2016). 
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*When retrospective assessment is required in licence conditions
Advice and input Application pathway Feedback and review
Feedback on project
Colleagues, per review
Named persons, unit staff
AWERB hubs
Home Office inspectors
Independent assessors
Home Office inspector 
and AWERB advice 
Feedback on process
Reporting to ASRU*
APPLICANT HBA – 
applies personal values in 
context of training and 
awareness of local culture
AWERB HBA – applies 
local values and shapes 
institutional cultures of care
ASRU HBA – applies 
legal framework and 
‘national’ values
DECISION on licence and 
conditions communicated 
to applicant
AWERB HBA – 
retrospective review of all 
projects, retrospective 
assessment of all severe 
procedures using ‘special’ 
and endangered species, 
most education and training 
projects
Learning from review
ASC HBA – advice via 
Secretary of State on 
severe procedures on 
special species, societal 
concerns and other 
issues specified in ASPA 
section 9[1]
Formal legal processes
Discussion, informal
advice
Key
Figure 1: Harm-benefit analysis, advice and feedback processes for project licence applications
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Here the ASC proposes an alternative flowchart, 
which:
• illustrates the HBA processes that operate 
before and after licensing decisions 
• identifies the range of personal local and 
national values that inform these judgements
• demonstrates the feedback processes which 
offer further points to review the HBA
Figure 1 (see p19) puts the applicant at the start 
of the HBA process. Researchers are responsible 
for the design and conduct of research using 
animals, in conjunction with associated named 
veterinary and animal care staff. They have specific 
legal obligations and are responsible for applying 
good practice principles around the 3Rs, research 
reporting and the development of appropriate 
mechanisms for realising the benefits from animal 
use and testing. 
Many funding bodies require researchers to make 
the ethical case for the use of animals in grant 
proposals. Funders and the peer review process 
also have an important role in assessing the 
validity, necessity and justification of the proposed 
research. The most recent Responsibility in the 
use of animals in bioscience research (NC3Rs 
et al., 2017) provides guidance to researchers, 
AWERBs and others about the expectations of a 
wide range of bodies who fund the use of animals 
in research1. It refers to the responsibilities of 
those involved in funding for deciding “whether 
the potential benefit justifies the possible adverse 
effects to the animals” (ibid p11). These are 
generally structured around harms and benefits, 
but individuals and bodies may have different 
views on HBA, dependent on their perspectives 
and priorities and will not necessarily employ the 
same criteria. 
1  This includes including The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), Biotechnology and 
Biological Sciences Research Council (BBSRC), Department for Environment, Food & Rural Affairs (Defra), Engineering and Physical Sciences 
Research Council (EPSRC), Medical Research Council (MRC), Natural Environment Research Council (NERC), Wellcome Trust and other 
Association of Medical Research Charities (AMRC) charities.
The AWERB should be recognised as a lynchpin 
within the HBA process, as it brings together a 
wide variety of relevant perspectives and operates 
within the establishment, enabling it to take 
account of local expertise and knowledge that 
might impact on the HBA. Guidance for HBA is 
available for AWERBs (European Commission, 
2014; Home Office, 2014, for example, p48, 
Chapter 10 and Appendix I, p125; Jennings and 
Smith, 2015; RSPCA/LASA, 2015). 
Aside from HBA per se, AWERBs also have 
responsibility for other relevant tasks, such as: 
• advising on animal welfare and the application 
of the 3Rs 
• retrospective assessment, which follows the 
development and outcome of projects
• providing a forum for discussion and 
development of ethical advice to the 
establishment licence holder (Hawkins and 
Hobson-West, 2017) 
• The development of a network of AWERB 
hubs has the potential to strengthen the role 
of AWERBs in relation to HBA, by providing 
opportunities for exchange 
The ASC also plays a role in this process, in its 
review of those licence applications which are 
referred to it. 
This ASC report seeks to contribute to developing 
a robust, inclusive and iterative HBA process by 
introducing new developments in the assessment 
of harms and benefits, exploring ways of engaging 
societal concerns and enhancing learning across 
these different processes.
This ASC report seeks to contribute 
to developing a robust, inclusive and 
iterative HBA process by introducing new 
developments in the assessment of harms 
and benefits, exploring ways of engaging 
societal concerns and enhancing learning 
across these different processes.
ASSESSING 
AND REDUCING 
HARMS
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3. Assessing and Reducing Harms 
3.1. INTRODUCTION
Predicting harms and assessing the actual 
harms experienced by animals used for scientific 
purposes is a critical part of the process of HBA. 
In this chapter, the ASC addresses three key areas 
relating to harms:
• reviewing the processes of identifying and 
assessing harms
• examining ways of incorporating cumulative 
effects in the HBA
• identifying strategies for minimising and 
potentially eliminating severe suffering 
All three of these areas are vitally important in 
ensuring that the potential harms to an animal 
are fully identified, minimised as far as possible 
and then evaluated, so that they can be weighed 
against the project licence applicant’s assessment 
of potential benefits in the HBA process.
The ASC make a series of recommendations 
around the assessment and reduction of harms 
in the HBA in this chapter. Some of these may 
be considered foundational to the assessment 
of the harms involved in animal research and 
testing and are reflected in the HBA advice 
note (ASRU, 2015). The critical importance of 
considering harms from the animals’ perspective 
means these responsibilities are restated here 
as principles for all processes of HBA. Others 
are medium- and longer-term recommendations 
for developing new scientific techniques and 
institutional opportunities for measuring, assessing 
and reducing the harms experienced by animals 
used for scientific purposes. 
3.2. IDENTIFYING AND 
ASSESSING HARMS 
Since the implementation of the UK Animals 
(Scientific Procedures) Act 1986 (A(SP)A) and the 
Animal Procedures Committee (APC) report 2003 
there have been significant advances in animal 
welfare science.  
A great deal more is now known about:
• the impacts of many procedures on 
animal welfare 
• the amelioration of the impacts by refinement 
or clinical intervention
• the positive and negative effects of different 
housing, husbandry and care protocols
Additional techniques have been developed and 
employed to assess welfare impacts on animals, 
including: 
• behavioural and other indicators of pain 
and suffering (European Commission, 2013; 
Sneddon et al., 2014) 
• physiological markers of stress, for example, 
hormonal or other parameters (Lane, 2006) 
or distress such as stereotypies (Mason and 
Latham, 2004) 
• tests of motivation to avoid potentially 
stressful situations (Dawkins, 1990; see also 
Dawkins, 2012)
• most recently, integrative markers of lifetime 
stress such as changes in telomere length 
(Bateson, 2016) or changes in specific brain 
areas such as the hippocampus (Mahar, 2014) 
Such methods can be used to inform prospective 
and ongoing assessments of harm and assist 
with retrospective assessments of actual harms. 
Animal welfare assessment is a growing area of 
development but there are also many knowledge 
gaps, such as the interpretation of some 
behavioural signs that may indicate the onset 
of either cumulative suffering or habituation. 
Further research to generate, evaluate and critically 
integrate data on acute and chronic harms to 
animals will contribute to strengthening evidence 
around harms for the HBA. 
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Recommendation 1
Data on animal welfare, including cumulative 
suffering, should be systematically collected in a 
format that allows comparison with other studies 
of a similar nature. Ideally, common reporting 
standards should be developed to facilitate such 
comparisons, for example, through publication, 
data repositories and the AWERB hubs.
There is also a place for the use of cautious 
anthropomorphism whereby, when evidence is 
lacking, it is reasonable to give animals the ‘benefit 
of the doubt’, by assuming that a procedure that 
causes pain, suffering, distress, or lasting harm to 
humans may also cause similar welfare problems 
in non-human animals, unless and until evidence 
to the contrary emerges.
3.2.1. IDENTIFYING HARMS 
EXPERIENCED BY ANIMALS
The ASRU HBA advice note (2015) explains that 
applicants for project licences are “asked how 
they will minimise suffering whilst achieving their 
objectives” and must define specific, practical 
strategies for implementation of the 3Rs (the 
replacement, refinement and reduction of the 
use of animals in research). Applicants are also 
required to define humane end-points that “serve 
as absolute upper limits (or caps) to the nature and 
level of suffering that an animal will experience”. 
The prior Animal Procedures Committee (APC) 
review suggests that assessments should 
consider what the harms actually mean for the 
animals in practice – for example, they should 
identify “social and psychological effects such as 
fear, anxiety … confusion and boredom, as well as 
more overt physical harms” (APC, 2003).
The HBA advice note (ASRU, 2015, pp14-16) also 
emphasises that the assessment and reduction 
of harms should cover all relevant impacts on the 
animals and should cover:
• project-related harms, ie those specific to the 
regulated procedures 
• contingent harms, which include “husbandry 
and care practices and transportation” (Home 
Office, 2014, p128)
2  The guidance on the operation of the Animals (Scientific Procedures) Act 1986 (A(SP)A) suggests that “on occasions it may be necessary to use 
a greater number of animals than the absolute minimum scientifically justifiable if each individual animal will suffer less as a consequence of the 
greater number being used” (Home Office, 2014, p13).
• cumulative effects, ie the net impact on 
animals of all the events and effects due to both 
procedures and husbandry, which requires 
further explanation of how such effects can be 
identified, assessed and taken into account 
within HBA.
See the Glossary for fuller definitions. 
It is also generally accepted that minimising 
the suffering of individual animals should take 
precedence over minimising the number of 
animals used, ie in circumstances where reducing 
the number of animals would cause each 
individual to suffer more severely (for example, 
if more invasive procedures were required to 
obtain equivalent data).2
Recommendation 2
Realistic estimation of the harms likely to be 
experienced by individual animals undergoing 
licensed procedures is critical throughout the 
different processes of HBA. Harms arising from all 
sources (not just procedures, as it is not significant 
to animals where the harms come from) should 
be taken into account by researchers, reflected on 
by AWERBs as part of their responsibilities for the 
application of the 3Rs and considered in the HBA. 
3.2.2. SPECIES AND EVIDENCE IN 
THE ASSESSMENT OF HARMS
Assessments of and efforts to avoid harms should 
always be based upon welfare data relating 
to the particular species involved. Within the 
text of the A(SP)A, there is an implied hierarchy 
between species at certain points, including when 
those applying for licences must ensure that 
the procedures; “involve animals with the lowest 
capacity to experience pain, suffering, distress, 
or lasting harm” (Part 3, 181[b]). 
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In addition, the A(SP)A explicitly offers additional 
protection to some species (cats, dogs, Equidae 
and non-human primates).3 
The ASC suggests that it cannot be assumed 
that the severity experienced by these species is 
greater than that experienced by any other species 
covered by the A(SP)A. Social science research 
on the implementation of this aspect of the A(SP)
A (Hobson-West and Davies, 2017) suggests, 
instead, there is more ‘societal sentience’ around 
these animals. This includes recognition of close 
cultural relationships with companion species 
and awareness of the potential for greater societal 
harms in the use of these animals. Recent science 
also suggests humans may be more responsive to 
the suffering of certain species due to the recent 
co-evolutionary histories of domesticated species 
(Nagasawa et al., 2015).
The capacities of species, the affordances 
provided to animals by laboratory environments 
and the close cultural relationships which humans 
have with certain animals do suggest that some 
species may have needs that could be more 
easily met in laboratory settings, with harms more 
readily ameliorated and for which there are fewer 
societal concerns. 
However, the ASC suggests that neither 
phylogenetic proximity to humans, close cultural 
relationships nor neurophysiological complexity 
necessarily mean that a given species will suffer 
more than any other species when undergoing 
a given procedure. Judgements about the 
relative severity of a given procedure for a given 
species can only be made where there is clear 
comparative scientific evidence that a procedure is 
more or less severe for one species than another.
3  These protections are outlined in the guidance on the operation of the A(SP)A (Home Office 2014). Permissions to use these species are 
only given if the purpose of the work specified in the licence can be achieved only by their use; or where it is not practicable to obtain other 
suitable animals. Projects involving these species are subject to retrospective review and proposals for procedures causing severe suffering in 
these species is subject to further review by the ASC. Funders of research intending to use these species may also require additional review of 
research proposal by the NC3Rs.
Recommendation 3
Scientists should accept their responsibilities to 
research and obtain expert advice on factors 
affecting the welfare of their study species, 
recognising the impact on science as well as 
animal welfare. Wherever possible the HBA should 
be based on recent scientific evidence regarding 
harms. Where these data are not available, 
efforts should be made to obtain data through 
sharing across organisations, for example, via 
AWERB hubs and identifying priorities and funding 
for future research, for example, via the NC3RS.
3.2.3. PROSPECTIVE ASSESSMENT 
OF SEVERITY CATEGORIES
The term ‘severity’ represents “the intensity 
of pain, suffering, distress or lasting harm 
experienced by an animal during a procedure” 
(Home Office, 2014, p8). For the purposes of HBA, 
prospective assessments of the potential harms 
to animals are required to determine a severity 
category for each protocol within a project 
licence. The assessments are based on ‘worst 
case scenarios’, which each define an upper limit 
to the suffering that an animal may experience in 
a given protocol (ASRU, 2015, pp16, 18). There 
is a detailed definition of ‘severity limits’ in the 
Glossary of this report.
Severity limits for regulated procedures are 
classified according to one of four categories:
• non-recovery 
• mild 
• moderate 
• severe
Each category is fully defined under severity 
categories in the Glossary.
However, as the HBA advice note (ASRU, 2015, p14) 
points out, determining a severity limit is not sufficient 
to assess harms fully and “information regarding the 
nature, incidence or duration of the harms or the 
percentage of animals affected also has to be taken 
into account”, along with details of each protocol, 
which will help determine “the different levels of 
severity likely to be experienced within that protocol”.
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3.2.4. RETROSPECTIVE (ACTUAL) 
ASSESSMENT OF SEVERITY 
Since 2014 actual severity assessments have 
also been required. These take place after 
the procedures are completed and reflect the 
actual harms caused to each individual animal 
in a given procedure, disregarding contingent 
harms. The evaluations are based on ongoing 
observations of each animal during day-to-day 
welfare assessments and record the highest 
level of suffering experienced by an individual 
animal during a procedure, taking account of 
any cumulative effects on suffering (ibid). 
The categories are the same as for prospective 
classification, with the addition of ‘sub-threshold’, 
which is used when actual severity turns out 
to be lower than the threshold for regulation of 
animal procedures (for example, below the level 
of pain, suffering, distress, or lasting harm caused 
by a skilled insertion of a hypodermic needle). 
Severe retrospective assessments encompass 
a variety of situations. Sometimes the suffering 
is well known in accordance with the legislation. 
Other times, severe is used as a principle of 
precaution when animals are ‘found dead’ in 
unknown circumstances, as the level of suffering 
they have experienced is unclear and could well 
have been severe.
Actual severity should be carefully and accurately 
recorded wherever possible. Actual severity 
assessments should be discussed at AWERBs 
and are returned annually to the Home Office.
The recording of retrospective severity data 
presents a new opportunity for researchers, 
AWERBs and ASRU to refine the definition 
of severity categories for procedures, to 
develop strategies to reduce suffering within 
establishments and across procedures and to 
inform the overall HBA.
The recording of retrospective severity data 
presents a new opportunity for researchers, 
AWERBs and ASRU to refine the definition 
of severity categories for procedures, to 
develop strategies to reduce suffering within 
establishments and across procedures and 
to inform the overall HBA.
Recommendation 4
Retrospective severity assessments should be 
used by researchers, AWERBs and ASRU to 
inform HBAs for future applications that employ 
the same or similar procedures. Information 
gleaned from these assessments should offer 
opportunities for establishment AWERBs to reflect 
on their own retrospective severity data and to 
highlight areas for refinement to reduce suffering, 
whether it be mild, moderate, or severe.
3.3. INTEGRATING 
CUMULATIVE EFFECTS
The ASRU advice note on the HBA process lists 
“cumulative effects” as a harm, which is defined 
as: “The net impacts of all the events (procedurally 
and husbandry-based) and effects that affect 
adversely, positively and by way of amelioration, 
the welfare of an animal over its lifetime. 
They include likely habituation, potentiation and/or 
sensitisation and any temporal element in which 
recovery between events and memory of them 
and/or their consequences is likely to be affected.” 
(ibid)
This is broader than the definition of “cumulative 
effect” in the guidance to A(SP)A (Home Office, 
2014). This was defined as “the effect which 
occurs where, in a series of procedures, a second 
or subsequent procedure has a compound 
effect, which may be positive or negative, in terms 
of causing pain, suffering, distress or lasting 
harm.” The HBA advice note (ASRU, 2015) is 
correct to include not only cumulative effects 
due to procedures, but also the net impact of 
all life events – that is, the lifetime, or cumulative, 
experience of the animal.
This is a sound principle but as it acknowledges, 
experiences influence an animal’s perceptions 
of subsequent events for better or worse. 
For example, while animals can habituate to 
procedures, they can also become sensitised 
and less able to tolerate them. Whether cumulative 
effects are experienced as a cumulative increase 
in the severity of harms, that is cumulative 
suffering or cumulative severity, depends on a 
range of factors. 
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These include: 
• the species 
• characteristics of the individual animal 
• the procedures 
• housing, husbandry and care 
• whether animals can be (and are) trained to  
co-operate with procedures 
• the empathy of handlers
The ASC suggests that the concept of cumulative 
effects is essential.
For ethical and animal welfare reasons, it is right to 
consider the animal’s lifetime experience and it is 
widely recognised that each intervention applied to 
an animal should not be considered in isolation. 
For ethical and animal welfare reasons, 
it is right to consider the animal’s lifetime 
experience and it is widely recognised 
that each intervention applied to an animal 
should not be considered in isolation.
Recommendation 5
Consideration should be given by researchers, 
establishments and the regulator to the harms 
experienced over the whole lifetime experience  
of the animal, recognising the risks of considering 
the animal’s experiences in isolation and being 
aware of all potential sources of harm. 
As indicated, this attention to cumulative effects is 
present in the HBA advice note (ibid), but the ASC 
restates this again as an important principle to 
underpin all processes of HBA. 
However, the ASC also notes that it is difficult 
to predict and recognise cumulative effects 
objectively and reliably. This is especially the case 
where these are negative, with implications for 
what may be experienced as cumulative severity 
or suffering. This can result in inappropriate 
assumptions about an animal’s ability to habituate, 
or become sensitised to, scientific and other 
procedures. Thinking of cumulative severity as 
harms ‘stacking up’ until a severity threshold is 
reached is over-simplistic and the likely scenario 
in practice is much more complex. The ASC 
thus follows this recommendation with further 
discussion of research on and recommendations 
for predicting, measuring and recording 
cumulative severity.
These address the key question: How can 
cumulative severity be best understood, predicted 
and recognised and then factored into the HBA? 
For example, when might repeated or chronic 
mild severity interventions cross the threshold to 
become moderate? Might non-A(SP)A studies 
involving repeated or chronic sub-threshold harms 
result in a cumulative level of severity that is above 
the threshold, without this being recognised or 
alleviated? Or is there a risk that some procedures 
may go beyond their severity limits, including 
beyond severe, due to lack of recognition of 
cumulative severity? Answers to questions like 
these are essential if HBA is to be properly and 
rigorously applied. 
3.3.1. PREDICTING AN ANIMAL’S 
CUMULATIVE EXPERIENCES
If the concept of cumulative effects is to be 
robustly applied, understanding and assessing 
the net impact of life as a research animal will 
require thoughtful and informed consideration of 
the kinds of ‘life events’ and interventions that may 
affect the animal (either positively or negatively), 
their short- and long-term impacts and how these 
will affect the animal’s perceptions of subsequent 
events and interventions. 
This cannot be achieved without understanding 
what an ‘adverse effect’ means from an animal’s 
point of view, yet consideration of the animal’s 
actual experiences is not universal. For example, 
in the experience of ASC working group members, 
researchers often mistakenly think of unexpected 
adverse effects only, or regard adverse effects as 
what they wish to do to an animal, for example, 
a ‘needle stick’. To a laboratory mouse, the needle 
stick is but one event in a sequence that includes 
stressful capture, particularly if caught by the tail 
(Hurst and West, 2010), restraint, the pain of the 
needle stick, possible painful tissue distension, 
potential after-effects of the substance injected or 
its vehicle and a recovery period after return to the 
cage. If this happens multiple times, the animal 
will learn what is about to happen and may even 
predict this if injections are regular, which could 
add further stress and anxiety. This is far from 
trivial for the animal and represents much more 
than ‘just a needle stick’. 
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Thinking about harms in this way will help to 
answer the essential questions: 
• will the animal habituate or become sensitised 
• if the animal becomes sensitised, at what point 
will severity limits be approached 
• might the harm-benefit balance be altered so 
that the procedure is no longer justifiable?
In addition to direct harms caused by procedures 
and their after-effects, contingent suffering must 
also be considered. Russell and Burch (1959) first 
described this as the incidental harms caused 
by suboptimal animal husbandry or concurrent 
pathologies not related to study objectives. The 
HBA advice note (ASRU, 2015) cites contingent 
harms, giving examples of: 
• being housed in a cage (as opposed to ranging 
freely in the wild) 
• inability to express a wide range of natural 
behaviours 
• handling or transport stress 
• olfactory exposure to a large number of 
conspecifics (in the case of laboratory rodents 
housed in conventional caging) 
These and other factors will also affect the 
animal’s experience of experimental and other 
interventions. There are different frameworks 
that can be used to assist in the identification of 
contingent suffering and their impacts on quality 
of life. These have also been revised following 
the APC (2003) review, with implications for the 
assessment of cumulative effects and severity. 
The HBA advice note cites the ‘Five Freedoms’, 
developed by the Farm Animal Welfare Council 
(FAWC) from the Brambell Report (1965), 
suggesting that any compromises of these 
could also be used to help to identify contingent 
suffering. These were originally listed as:
• Freedom from hunger or thirst 
• Freedom from discomfort 
• Freedom from pain, injury, or disease
• Freedom to express normal behaviour 
• Freedom from fear and distress 
The Five Freedoms concept has been reviewed, 
principally because the original formulation related 
to avoiding negatives rather than promoting 
positives. FAWC (2009) more recently defined 
welfare in terms of the promotion of positives 
and suggested that one should consider positive 
feelings (what an animal likes) and the resources 
that they are motivated to obtain (what an  
animal wants). 
FAWC and others have subsequently defined 
categories of welfare that relate to an animal’s 
quality of life and total lifetime experience as: 
• a ‘good life’ 
• a ‘life worth living’ 
• a ‘life worth avoiding’
• a ‘life not worth living’ 
A more recent development in thinking is the ‘Five 
Domains’ model of welfare (Mellor, 2016), which 
comprises: 
• nutrition/hydration 
• environment 
• health/functional status 
• behaviour
• mental state
A paper by Littlewood and Mellor (2016) describes 
how the ‘Five Domains’ approach can be 
used to grade negative and positive states in a 
fictitious scenario following a working dog before, 
during and after an injury, through to rehoming 
as a companion animal. Although this is not 
an example in a research setting, it is useful in 
demonstrating how animal welfare science and a 
quality of life assessment model can be used to 
predict how an animal may be feeling and make 
judgements over time.
Recommendation 6
Consideration of cumulative effects should be 
used by establishments to provide a focus for 
increasing the animal’s positive experiences. 
Any assumptions about an animal’s ability to 
habituate to procedures, or conversely to become 
sensitised, should be critically scrutinised, 
by researchers, AWERBs and regulator. 
Suggestions that an animal habituates should 
be verified with empirical, objective evidence.
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3.3.2. DETECTING AND ASSESSING 
CUMULATIVE SUFFERING 
The following sections focus on assessing 
cumulative suffering, on the basis that in the 
context of animal experimentation it is usual to 
prioritise detecting and ameliorating negative 
cumulative effects, as opposed to detecting 
positive effects. However, cumulative suffering will 
continue to be an abstract concept unless more 
reliable ways are developed to detect and assess 
it. For example, indicators are needed to detect: 
• when an animal has become sensitised to 
repeated procedures
• when an animal is no longer coping with life 
in the laboratory and all that this entails 
For the first, this could be indicated by 
exaggerated physiological and/or behavioural 
responses to a ‘routine’ procedure, whereas 
the second instance will involve chronic stress. 
The latter may be evidenced by stereotypic 
behaviour and/or apparent depressive symptoms, 
but more sensitive early indicators should prevent 
the animal’s welfare state falling to these levels.
Ideally, an effective, comprehensive and properly 
implemented welfare assessment protocol 
would be able to detect when acute responses 
to procedures are heightened. Further research 
would be required to evaluate whether it is being, 
or could be, achieved. At the time of writing 
(August 2017), the ASC HBA subgroup was not 
aware of any objective indicators that have been 
developed and validated for chronic stress. 
An attempt was made to assess the potential 
for cumulative severity in non-human primates 
used in neuroscience research by the APC 
primate subcommittee. This found ‘little evidence’ 
for adverse cumulative severity. However, 
the ‘Pickard Report’ relied to a large extent on 
qualitative data (in the form of the views from 
self-selected practitioners) and did not include 
objective indicators of animal welfare apart 
from body weight and ‘willingness’ to perform 
behavioural tests (APC Primate Subcommittee 
Working Group, 2013). 
4  See: https://nc3rs.org.uk/assessing-cumulative-severity-macaques-used-neuroscience-research (last accessed 8/9/2017)
The ASC raised the lack of objective indicators in 
a response to the APC primate subcommittee’s 
report (ASC, 2014), further pointing out that: 
• there is debate as to whether ‘willingness’ 
to perform tests can be used as a welfare 
indicator 
• the practitioners who participated were a  
self-selecting sample
• there is a need for further work based on 
larger, more meaningful datasets derived from 
systematic sampling
Although the ASC is not aware of current 
systematic studies of cumulative severity  
using data from significant numbers of animals  
(of any species), some novel approaches 
to defining and evaluating indicators are in 
development. It is hoped that these will be able 
to indicate the long-term experience of an animal 
and be useful ‘measures’ of cumulative severity. 
Some novel approaches to defining and 
evaluating indicators are in development. 
It is hoped that these will be able to indicate 
the long-term experience of an animal and 
be useful ‘measures’ of cumulative severity.
One example is telomere attrition, in which 
telomeres (repeated sequences of DNA at 
the ends of each chromosome, which have a 
protective function and naturally shorten with age) 
become significantly reduced in length because 
of chronic stress. This can be evaluated by 
analysing blood or cheek cell samples. Studies are 
ongoing in a number of species including humans 
(Bateson 2016). 
Another potential measure is the volume of grey 
matter in the hippocampus, which has been 
evaluated using magnetic resonance imaging (MRI) 
in the rat (Lee et al., 2009), extensively in humans 
and, in an ongoing project, the macaque.4 
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Both telomere attrition and hippocampal volume 
loss appear to be reversible. This could make 
them especially useful tools for understanding 
harms to animals and assessing potential 
refinements, if correlations with cumulative 
severity levels are demonstrated and evaluated.
Both approaches can also be measured 
repeatedly during the animal’s lifetime, allowing 
for longitudinal assessments. The equipment and 
analysis required would preclude widespread and 
routine use of these techniques and there may be 
harms imposed by multiple bouts of anaesthesia. 
However, they may be helpful for understanding 
the welfare impact of chronic protocols, or those 
involving repeated technical acts, with the aim of 
improving the accuracy of severity classifications, 
evaluating refinements and defining more humane 
end-points.
This is an area that requires more research and 
there is a need for large, meaningful datasets 
and systematic sampling of procedures, 
plus quantitative data on a range of parameters 
obtained via detailed, longitudinal studies. 
Recommendation 7
Funders, including the NC3Rs, should consider 
further funding research into behavioural and 
physiological indicators of cumulative severity 
and into assessing the affective states of animals 
in research. Researchers should explore if this 
can be done by obtaining valid data from animals 
already undergoing regulated procedures, to avoid 
causing additional harms.
3.3.3. RECORDING AND 
REVIEWING INDICATORS OF 
CUMULATIVE SUFFERING
In order to be alleviated and considered in 
HBA, cumulative suffering has to be effectively 
monitored and reviewed. With respect to chronic, 
negative cumulative effects, some animals have 
adaptive capacities that allow them to withstand 
the negative effects of certain conditions, whereas 
others undergo sensitisation such that adverse 
effects may be potentiated. 
However, for all animals there will be a 
‘tipping point’ when their welfare will become 
unacceptably compromised and an ideal 
recording and reviewing system would help 
to predict, or at least rapidly detect, when this 
point occurs. 
Concurrent with the development of research on 
behavioural and other signs that may indicate the 
onset of either cumulative suffering or habituation, 
the ASC suggests that recording techniques are 
used during to both monitor animals and carry out 
further research on cumulative severity. 
Recommendation 8
AWERBs should be encouraged to engage with 
new research tools for recognising and recording 
cumulative severity. These could be used to 
assist and develop the HBA by advising the 
establishment licence holder whether to support 
project proposals, following the development and 
outcome (retrospective review) of projects and 
providing a forum for discussion and development 
of ethical advice, including via AWERB hubs.
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The following example is based on work by HBA subgroup member, Professor Wolfensohn (Honess and 
Wolfensohn, 2010; Wolfensohn et al., 2015).  
The animal welfare assessment grid 
One example of a recording system that takes into consideration the impact of direct suffering (due to 
scientific procedures) and contingent suffering is the animal welfare assessment grid (AWAG). 
This has been developed in a collaboration between Public Health England (PHE) and Surrey University 
Veterinary School. Technical and download information for the current AWAG software system is 
available at their website (https://github.com/PublicHealthEngland/animal-welfare-assessment-
grid/wiki). There is further background and some examples of the grid being used in research available 
via the NC3Rs website (https://crackit.org.uk/improving-animal-welfare-using-animal-welfare-
assessment-grid-awag).
This tool can be used to evaluate and monitor the animal’s clinical condition and behavioural deviations, 
in the context of scientific procedures and the animal’s living environment. It provides graphic illustrations 
of an animal’s likely quality of life, at a single point and over time.
Figure 2: An animal welfare assessment grid at a single point in time (Source: Dennis et al., 2015) 
The size and shape of the central box of the chart will vary according to the severity of each of  
the four factors: 
• experimental/clinical events, reflecting suffering 
• clinical condition, reflecting physical well-being
• behavioural deviations, reflecting psychological well-being
• quality of the environment, reflecting contingent suffering due to husbandry
This approach provides an immediate and straightforward way of visualising the extent of the 
harms across all four domains, to highlight the key factors that are having the most detrimental effect. 
This enables refinement to be closely targeted and improvements in welfare and reductions in suffering 
to be maximised. 
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Comparing consecutive AWAG assessments is particularly helpful in assessing cumulative suffering,  
as it shows the peaks and troughs of the harms caused to the animals over time.
Figure 3: Illustration showing changes in the animal welfare assessment grid resulting from  
a welfare-challenging event (Sources: Honess and Wolfensohn, 2010)  
A system like the AWAG could be used for project planning and both interim and retrospective reviews 
of an animal’s welfare status (Honess and Wolfensohn, 2010; Wolfensohn et al., 2015). It also offers the 
opportunity to consider ways of reducing cumulative severity, for example, in assessing whether leaving a 
longer time between procedures is an advantage for the animal by allowing more time for adaptation and 
habituation, or whether it adds to the overall severity, for example, by increasing the time the animal must 
spend in a less than ideal environment.
3.3.4. EVALUATION AND NEXT STEPS
It is an essential acknowledgement of the facts 
that repeated scientific procedures conducted on 
an animal cannot be considered in isolation. An 
animal’s other, non-procedural (ie contingent) life 
experiences can have a significant influence on the 
intensity and nature of suffering due to procedures. 
The temporal impacts of both chronic procedures 
and life in the laboratory in general, are also 
fundamental to the concept of cumulative severity.
Understanding cumulative severity requires 
consideration of the animal’s lifetime experience, 
including sourcing, husbandry and care issues, 
study design and methodology, interventions to 
minimise adverse effects, end-points and  
humane killing.
Understanding cumulative severity 
requires consideration of the animal’s 
lifetime experience, including sourcing, 
husbandry and care issues, study design 
and methodology, interventions to 
minimise adverse effects, end-points and  
humane killing.
However, validated indicators of chronic stress, 
such that an animal is beginning to lose the ability 
to cope with life in the laboratory, are lacking. 
Systems that will enable longitudinal recording 
of welfare indicators and inputs (for example, 
husbandry refinements), such as the AWAG, 
are being successfully developed. These may 
help to identify both chronic stress per se and 
sensitisation, indicated by increased responses to 
‘routine’ procedures.
A B
A B
C
volume volume
The welfare-challenging event occurred at time-point B.
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Until more work has been done to develop 
and validate objective indicators of long-
term cumulative suffering and to ensure that 
sensitisation is being effectively detected, factoring 
cumulative suffering into HBA will continue to be 
subjective and assumptions will be made that may 
or may not be appropriate. Our recommendations 
focus on the opportunities for research, exchange 
and review to develop frameworks to further the 
knowledge and assessment of cumulative effects. 
3.4. MINIMISING 
SEVERE SUFFERING
Any type and degree of suffering caused to an 
animal should be taken seriously and minimised as 
far as possible. However, as would be expected, 
there is particular concern about procedures that 
cause severe suffering, in which animals are likely 
to experience “severe pain, suffering or distress, 
or long-lasting moderate pain, suffering or distress, 
as well as procedures that are likely to cause 
severe impairment” (Home Office, 2014).
In relation to upper limits of severity, procedures 
that may cause an animal “severe pain, suffering or 
distress that is likely to be long-lasting and cannot 
be ameliorated” are prohibited by UK project 
licence Standard Condition 7 (Home Office, 2014). 
This is also reflected in Article 15(2) of Directive 
2010/63/EU, but can be subject to the use of the 
so-called ‘safeguard’ clause in Article 55, whereby 
if there are exceptional scientifically justifiable 
reasons a provisional measure can be adopted to 
allow the procedure. 
However, in this case the European Commission 
and other EU Member States must immediately be 
informed and within 30 days the Commission will 
either authorise or revoke the provisional measure. 
In this section, the ASC discusses strategies 
for reducing severe suffering, with the goal of 
eliminating it altogether. First it examines the 
levels of severe suffering actually experienced by 
laboratory animals.
3.4.1. RETROSPECTIVE DATA 
ON SEVERE SUFFERING 
Since 2014, the annual publication of data on 
actual (retrospective) severity of procedures, 
as reported by licence holders, has provided 
information on the extent of severe procedures, 
including by species and purpose of the 
procedure. Table 1 below shows total 
retrospective, ie actual, severity assessments 
for 2014, 2015 and 2016. The table shows that, 
overall, 114,000 animals experienced severe 
suffering in 2016 (6% of all animals used). 
There are some questions around the 
comparability of these data. However, it appears 
to indicate that actual numbers of experimental 
procedures recorded as causing severe suffering 
went down between 2014 and 2016. Conversely, 
the number of procedures retrospectively identified 
as causing moderate suffering has increased. 
Moderate suffering is a wide category band, 
which is explored in Section 3.4.4.
Table 1: Actual severity of suffering recorded in experimental procedures on animals, 2014-2016
2014 data 2015 data 2016 data
Number of 
procedures %
Number of 
procedures %
Number of 
procedures %Actual severity category
Sub-threshold 180,121 9 268,455 13 235,000 12
Non-recovery 132,770 7 123,079 6 154,000 8
Mild 975,513 51 1,063,585 51 938,000 46
Moderate 483,262 25 501,620 24 581,000 29
Severe 149,917 8 123,231 6 114,000 6
Total 1,925,583 100 2,079,970 100 2,022,000 100
Source: Home Office (2015b, 2016, 2017)
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Table 1 excludes data for the creation and breeding of genetically altered animals (1.91 million in 2016, 
of which 67% were assessed as sub-threshold, 29% mild, 3% moderate and 2% severe).
Table 2 below shows the number of procedures recorded as causing severe suffering, broken down by 
species. The largest group experiencing severe suffering were mice: with a total of 101,494 procedures 
(8% of all those on mice) retrospectively classified as having caused severe suffering.
5  No cats or horses experienced severe suffering; there were no procedures on reptiles or cephalopods in 2015.
Table 2: Actual severe suffering recorded in experimental procedures, by species, 2015
Species
Number of procedures 
retrospectively classified 
as severe procedures
Total number of 
procedures
% of severe 
procedures
Mouse 101,494 1,264,501 8.0
Rat 3,358 257,665 1.3
Guinea pig 2,004 21,831 9.1
Other rodent 105 3541 2.9
Rabbit 180 14,155 1.2
Dog 3 4,643 0.06
Ferret 1 626 0.16
Pig 14 2,895 0.4
Other ungulate 12 40,387 0.03
Other mammal 12 871 1.4
Primate 28 3,612 0.8
Bird 1,466 140,724 1.0
Amphibian 1,863 10,333 1.8
Fish 12,633 293,558 4.3%
TOTAL 123,231 2,079,970 5.9%
Source: Home Office (2016)5
The number of animals experiencing severe suffering also varied according to the procedure involved. 
As shown in Table 3, regulatory testing was the most common cause of severe suffering, both numerically 
and proportionally (see section 4.3.5).
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Table 3: Actual severe suffering recorded in experimental procedures, by purpose, 2015
Purpose of 
procedure
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Total
Number 
of animals 
experiencing 
severe suffering 
23,202 11,647 344 0 0 0 88,038 123,231
Total number of 
procedures 1,102,096 401,811 17,741 757 1,845 0 555,720 2,079,970
Percentage of 
total that were 
severe
2.1 2.9 1.9 0.0 0.0 0.0 15.8 5.9
Source: Home Office (2016)
Given the extent of severe suffering, there is clearly 
a need to consider additional levels of scrutiny 
for the most severe procedures and investigate 
ways of refining severe suffering, with the aim of 
eliminating it altogether.
3.4.2. SCRUTINY OF THE USE OF 
SEVERE PROCEDURES
When considering the use of severe procedures, 
the first step should be to refine the procedures as 
fully as possible to reduce their severity. 
When considering the use of severe 
procedures, the first step should be to 
refine the procedures as fully as possible 
to reduce their severity. 
This should include consideration of whether, 
after application of the 3Rs, the level of harm 
caused to the animals will be so high that it 
cannot be justified, whatever the benefits might be.
In some instances, applications to use severe 
procedures are referred to the ASC, alongside 
other potentially contentious projects. Specific 
circumstances in which projects might or must 
be reviewed by the ASC are listed below.
Published criteria for referral to the ASC
Severe (as well as complex and/or contentious) 
projects and procedures are scrutinised within a 
referral framework. This may involve inspectors 
with relevant specialist training, inspector review 
and case discussion panels and independent 
assessors. In addition, the Secretary of State may 
refer project licence applications to the ASC for 
advice, especially applications involving use of:
• wild-caught non-human primates 
• cats, dogs, Equidae or non-human primates 
in severe procedures
• endangered species 
• admixed embryos (under certain 
circumstances)
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• any of the ‘safeguard clauses’ in Directive 
2010/63/EU with respect to the purpose 
of primate use, proposals for the use of a 
great ape, or proposals to cause long-lasting 
pain, suffering, or distress that cannot be 
ameliorated6
• projects with major animal welfare or ethical 
implications
• raising novel or contentious issues, or giving 
rise to serious societal concerns.
Whether or not applications to carry out severe 
procedures are referred to the ASC, steps 
can be taken to enhance the assessment and 
amelioration of harms.
• Pre-approval scrutiny of procedures can 
be used to determine the conditions under 
which the licence might (or not) be approved. 
For example, a licence may be granted for a 
short initial period to allow for pilot studies, with 
clearly defined humane end-points, to assess 
the actual effects of the procedures and where 
possible mitigate them. Similarly, where novel 
studies are concerned, there should be an early 
review of potential issues of concern to identify 
opportunities for refinement. Ideally, the findings 
of any such studies would contribute to the 
research dataset, to avoid using any additional 
animals. 
• Post-approval scrutiny by the researchers 
and the institutional AWERB should clarify the 
severity actually experienced by the animals, 
the effectiveness of attempts to mitigate 
severity and the balance of realised benefits 
versus harms. This should demonstrate 
clear progress in reducing harms, based on 
presentation and discussion of relevant data 
and the dissemination of knowledge about 
actual severity in such circumstances. This 
stage review should enable further refinement 
of the techniques and prevent the use of severe 
procedures wherever possible.
Where severe suffering is unavoidable, 
there should be an exceptionally high level of 
benefit and likelihood of achievement.
6 If any such exemptions were supported, it would require legislative amendment in the Houses of Parliament.
Where severe suffering is unavoidable, 
there should be an exceptionally high level 
of benefit and likelihood of achievement. 
Whenever procedures are carried out, their 
classification must be kept under review, so that 
issues affecting severity arising during a procedure 
can be re-evaluated and if necessary reclassified 
– for example, with experience of the work, a 
moderate procedure may be reclassified as severe 
(or vice versa). 
Throughout the above scrutiny processes, the 
option ‘just to say no’ must remain on the table 
and be employed whenever there is sufficient 
concern about the severity of harms and/or the 
balance of benefits over harms.
The ASC identifies two recommendations to 
support the challenge provided by projects 
involving severe procedures prior to submission to 
ASRU by the researcher and AWERB: and to draw 
attention to the opportunities for scrutiny post-
approval, including in subsequent reporting and 
publication. 
Recommendation 9
Researchers and AWERBs involved in developing 
and/or reviewing project licence applications prior 
to submission should always provide a robust, 
constructive challenge to the scientific need and 
the ethical justification for using a severe model 
or procedure . Support for this might be provided 
through additional components in existing training 
for AWERB members and exchange via AWERB 
hubs.
Recommendation 10
Projects that may cause severe suffering should 
be given intensive scrutiny at every stage of 
their design, in the ethical review process and in 
subsequent reporting and publishing. This should 
not only include scrutiny by the researchers 
involved, the AWERB, the Home Office inspector 
and in some cases the ASC – but also, where 
relevant, funding bodies and journal editors who 
publish research involving animals.
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3.4.3. STRATEGIES FOR MINIMISING 
AND ELIMINATING SEVERE SUFFERING 
This section examines ways of mitigating, 
minimising and avoiding procedures classified 
as severe under the definition above and in 
the Glossary. Finding new ways of working to 
avoid severe suffering is a challenge in which 
every establishment should participate, sharing 
strategies, obstacles and successes with each 
other wherever possible.
The Research Animals Department of the Royal 
Society for the Prevention of Cruelty to Animals 
(RSPCA) is working towards the ending of 
severe suffering and has developed a ‘Road 
Map’ strategy to help establishments to achieve 
that goal. The Road Map sets out a systematic 
approach, available as a paper and poster (Lilley 
et al., 2014a; 2014b). Key elements of this are 
summarised below.
Summary of key points in the Royal Society 
for the Prevention of Cruelty to Animals’  
Road Map towards ending severe suffering
The central premise of the Road Map is that 
“every establishment should ensure there is 
a process to achieve the following for severe 
‘models’ or procedures”, by acting on the following 
five key elements.
1. Culture. Establish and maintain a progressive, 
open-minded and caring research culture. 
An institutional ‘culture of care’ is a prerequisite 
for effective implementation of the Road Map.
2. Analysis. Establish to what extent severe 
suffering occurs. Perform an in-house ‘severity 
audit’ of all protocols, procedures and ‘models’. 
Establish where there is potential for severe 
suffering and what actual severity is experienced 
by individual animals.
3. Evaluation. Look at why severe suffering 
occurs and what current approaches are used  
to avoid it by considering the following questions.
• Why is the procedure used and what factors 
contribute to it being severe?
• Is severe suffering really necessary to achieve 
the scientific objective?
• What proportion of animals in each protocol, 
procedure or ‘model’ experienced severe 
suffering?
• What refinements are already in place, how 
effective are these and is there potential for 
further application of the 3Rs?
4. Define obstacles. Establish what the impact 
of ending severe suffering would be. What are 
the scientific obstacles to ending severe suffering? 
Set these out clearly and assess the genuine 
impact of stopping severe protocols, procedures 
or ‘models’. 
5. Overcome obstacles. Set out a plan to end 
severe suffering. 
• Take an alternative approach. For example: 
Use a non-severe model. Re-frame the 
research question to avoid a severe model. 
Use a mechanism-based approach rather than 
a disease-model approach.
• Apply refinement. For example: Refine every 
element of the lifetime experience of the animal. 
Establish, validate and implement humane 
endpoints.
 
The RSPCA approach offers opportunities for 
AWERBs in relation to this goal: 
• to consider the idea of ending severe suffering 
caused to animals within the establishment (and 
beyond) 
• to think creatively and share strategies, 
obstacles and successes with each other 
wherever possible
• to dedicate time and resources towards 
achieving that goal 
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Recommendation 11
Finding new ways of working to avoid and 
eliminate severe suffering is a challenge in which 
every establishment and its AWERB should 
participate. As projects progress and at their 
conclusion, feedback on successful refinements 
and ongoing concerns should be provided to 
all those within and across establishments (for 
example, via AWERBs and AWERB hubs) who 
have been involved in addressing severe suffering. 
The RSPCA’s Road Map offers a systematic 
approach and opportunity to address questions in 
the broader research community, such as whether 
severe procedures currently in use are necessary 
and whether and by how much a ‘ban’ on severe 
suffering would impact on research and testing.
3.4.4. WIDER CONSIDERATIONS 
REGARDING SEVERITY THRESHOLDS
It is important to acknowledge that harm 
categorisations, while useful in helping to ensure a 
consistent approach to regulation and compliance, 
are blunt instruments when dealing with the 
suffering of individual sentient animals. In EU 
legislation, the examples of severe procedures 
are a narrow subset that lies at the highest end 
of the severity classification. This means that: 
• the moderate classification includes a wide 
range of procedures, some of which many may 
regard as severe
• similarly, the mild category will also include 
a spectrum of procedures that range from 
just within the threshold for inclusion in the 
regulatory framework up to those that fall 
immediately below the threshold for the 
moderate category 
For that reason, those undertaking HBA need 
always to recognise the likely and/or actual 
experience of the animals involved and remember 
that each category of severity (mild, moderate 
and severe) includes a variety of procedures 
that differ (sometimes widely) in the level of their 
adverse effects.
The length of time that an animal is subjected to 
mild and/or moderate levels of suffering is also a 
critical point and can cause severity to cross the 
threshold from mild to moderate or from moderate 
to severe. Duration of suffering is a key element in 
consideration of cumulative suffering, which has 
been discussed in section 3.3 above.
The European Commission’s report (2012) on 
severity classification emphasises that determining 
severity classifications requires a team approach, 
which has several knock-on benefits, including: 
• increased opportunities to apply the 3Rs and 
improve animal welfare and, as a result, improve 
scientific data 
• enhanced transparency and communication 
between those using, caring for and 
monitoring animals
• increased understanding of how to assess 
severity, leading to greater consistency and 
provision of evidence-based information to help 
inform future severity categorisation 
The above report also provides a sample ‘scoring 
scheme’ to assist with consistency in severity 
classification and inform humane end-points.
It is also important to remember that each 
individual animal’s suffering is their own and 
that the number of other animals experiencing 
suffering makes no impact on the experience of 
the individual. Even if just one animal suffers at any 
level, efforts should always be made to avoid and 
mitigate that suffering.
Moreover, for all procedures, regardless of their 
severity, the benefits that accrue from the work 
should be as high as possible. However, those 
procedures that lie at the upper end of the severity 
classification must be subject to intensive scrutiny, 
taking into account a wide range of views and a 
balanced, thoughtful approach  
to HBA.
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Recommendation 12
It is important that researchers, establishments, 
AWERBs and inspectors all understand that each 
category of severity includes a range of adverse 
effects and that the moderate category includes 
a particularly wide range of procedures, some 
of which other people might regard as severe. 
Severity categories alone are blunt instruments 
for HBA and at all times the likely and actual 
experiences of the animals should be used as 
the measure of harms in the ethical weighing 
process. There is a legal requirement for the 
project licence holder to notify the Secretary of 
State if the severity limits or other controls are, 
or are likely to be, breached. When approaching 
the upper limit of any severity classification, there 
should be particular scrutiny by researchers and 
establishments of the duration of suffering , as 
long-lasting moderate suffering can cross from 
moderate into severe and similarly, long-lasting 
mild suffering can become moderate.
3.5. CONCLUSION 
This section has suggested the HBA cannot be 
properly conducted unless it takes account of 
all the harmful effects of scientific procedures, 
including contingent as well as direct project-
related harms and the cumulative effects of 
all the different impacts on animals over time. 
This has direct implications for methods of 
assessing animal suffering, implementing 
refinements, factoring in lifetime experiences 
and justifying procedures and research projects.
There are opportunities to learn from new 
assessment methods and emerging data on 
animal welfare and to refine the prospective 
assessment of harms from the recording of actual 
severity. Licence applicants and AWERBs play a 
key role in identifying, assessing and minimising 
harms and should seek opportunities to engage 
new tools and learn from other processes  
of HBA. 
There should be a specific focus on steps that 
can be taken to minimise severe suffering, with 
an ultimate goal of eliminating severe suffering 
altogether. AWERBs should take the idea of 
ending severe suffering caused to any animal 
within the establishment (and beyond) seriously, 
think creatively and dedicate time and resources 
towards achieving that goal.
One key intended outcome of this report is to help 
and encourage those who use and evaluate the 
use of animals in research to do things differently 
and better when identifying an animal’s suffering 
and other experiences (whether positive, neutral, 
or negative). Some recent changes to practice 
have come about from modifications to regulation, 
revised guidelines and public pressure. However, 
it is also important that mechanisms are available 
to initiate and support change emerging from 
voluntary “on the ground” improvement in relation 
to animal use among the scientific community
Recommendation 13
Applicants and AWERBs play a key role in driving 
and implementing change and should seek 
opportunities to improve. ASRU already provides 
feedback to the licence applicant following 
decisions on project licences. There should 
additionally be feedback to and when necessary 
review by, AWERBs when an inspector, or the 
ASC, identifies ethical or welfare concerns that the 
AWERB and the applicant have not identified or 
sought to address.
ASSESSING 
AND WEIGHING 
BENEFITS
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4. Assessing and Weighing Benefits 
7  http://www.ref.ac.uk/ (last accessed 8/9/2017)
4.1. INTRODUCTION
Under the UK Animals (Scientific Procedures) 
Act 1986 (A(SP)A) , project licences may only 
be granted for specified, permissible purposes 
listed in Section 5 of the Act (see Glossary) and 
only when: 
• there is no suitable alternative that would avoid 
the use of animals
• the number of animals to be used is optimised 
and suffering is minimised as far as possible
• the likely harms caused to the animals have 
been ‘weighed’ against the potential and 
likely benefits
While research on laboratory animal welfare 
has made considerable contributions to the 
assessment and minimisation of harms, direct 
research on the evaluation and enhancement of 
benefits from animal research has been more 
limited (though see Pound et al., 2004). 
Nevertheless, new ways of collecting and 
evaluating data on research benefits are becoming 
available. There is a growing international 
translational agenda within the life sciences, 
which seeks to facilitate the transfer of laboratory 
discoveries about disease mechanisms to 
clinical applications (Hobin et al., 2012). There 
are increasing demands from national funders 
and government for accountability, using metrics 
and processes such as the Research Excellence 
Framework (REF)7 to evaluate the investments 
made in research and understand the most 
effective pathways to impact. There is also 
increasing attention, led by learned societies 
like the Academy of Medical Sciences (AMS, 
2015), on scientific good practice, with the aim of 
understanding how research cultures and credit 
structures may hinder or enhance the reliability, 
reproducibility and integrity of scientific research. 
In addition, there is now more emphasis on 
public transparency. For example, the opening 
commitment of the Concordat on Openness 
on Animal Research in the UK (Understanding 
Animal Research, 2014, p6) requires signatories 
to “provide accurate descriptions of the benefits, 
harms and limitations of such research, 
[and] be realistic about the potential outputs 
of such research”.
These and other initiatives can be used to help 
assess potential benefits and weigh potential 
benefits against harms from animal research in 
HBA. However, they also indicate the challenges; 
ongoing debates around research integrity and 
outcomes suggest that the life sciences are not 
currently (as at August 2017) realising the expected 
benefits to human and animal health and the 
environment (Van der Worp et al., 2010; Garner, 
2014). 
In this chapter, the ASC considers the 
opportunities to improve the assessment and 
weighing of benefits in HBA. In Section 4.2 
it reviews the Animals in Science Regulation 
Unit (ASRU) advice on assessing benefits and 
discusses some common challenges across the 
evaluation of all benefits. 
In Section 4.3, the ASC then considers these 
opportunities to enhance the evaluation and 
realisation of benefits in HBA through: 
• the use of systematic review 
• attention to experimental design 
• identifying benefits from basic research 
• considering different pathways to translational 
research
• collaboratively evaluating the benefits 
associated with regulatory research and testing 
Chapter 5 explores further issues around 
incorporating societal concerns around the 
benefits from animal research. 
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4.2. CHALLENGES IN 
ASSESSING AND WEIGHING 
BENEFITS
The 2003 Animal Procedures Committee (APC) 
review concluded that the “evaluation of benefits 
and harms can be based only on potential, likely 
and probable, not certain, outcomes” (APC, 2003, 
p35) and that the weighing of harms and benefits 
is not a quantitative process – rather, it is a matter 
of judgement, which is always contestable (Smith 
and Boyd [eds], 1991). This fundamental challenge 
has not changed and this is acknowledged in the 
HBA advice note (ASRU, 2015). 
Whilst there are challenges in assessing and 
weighing both harms and benefits, the ASC 
suggests that there are additional issues in the 
evaluation of prospective benefits. The assessment 
of harms can be informed by previous experience 
of the outcomes of similar procedures, alongside 
the animal welfare science literature, enabling 
predictions about adverse effects and evaluation 
of how they might affect the animal in advance. 
Researcher experiences of and literatures around 
the realisation of benefits have yet to be organised 
in a similar way, with competitive pressures making 
this exchange less likely. 
Furthermore, the overall harms associated 
with a procedure or study can be assessed 
at one-time point after the study has 
ended, making to easier to check whether 
the prospective assessment of harms 
was accurate. 
Furthermore, the overall harms associated with a 
procedure or study can be assessed at one-time 
point after the study has ended, making to easier 
to check whether the prospective assessment of 
harms was accurate. 
In contrast, only short-term benefits and interim 
steps towards longer term outcomes can be 
checked in an analogous manner at the end 
of a project, with other elements of research 
benefits remaining open. The implications 
of these and other challenges are reviewed 
below, with particular attention to issues around 
cultures of science, timescales, checklists and 
ongoing reviews.
4.2.1. THE ANIMALS IN SCIENCE 
REGULATION UNIT ADVICE NOTE 
The HBA advice note (ibid) explains that “the 
benefits considered during the HBA are the 
specific, expected beneficial outcomes of the 
objectives of the project”. These include direct 
project-related benefits and indirect benefits to the 
wider research field or the 3Rs (the replacement, 
refinement and reduction of the use of animals in 
research), but exclude “the non-specific benefits 
of the area of research in general”. 
The Animals in Science Regulation Unit 
advice note review of benefits 
The HBA advice note lists the following 
questions (pp17-18) that are asked during the 
review of benefits.
• What will be the benefits of the work? 
For example, what data may be acquired, 
what drugs may be developed, what scientific 
questions may be answered, what knowledge 
gaps might be filled and what is the 
project’s output?
• Who and how many will benefit from the 
work? For example, other researchers? 
Human or veterinary patients? A relatively 
small set of patients, for example, people with 
a rare genetic disease? Potentially millions, 
for example, a vaccine candidate for malaria? 
The environment? 
• How will the benefits accrue? For example, 
improved scientific knowledge/understanding? 
New or more efficacious therapies? Cheaper 
therapies? An impact on patients’ quality of life? 
• When will the benefits be achieved? This 
can range from within the lifespan of the PPL 
(for example, toxicological safety testing) to 
decades in the future (for example, basic 
research into malarial immunology that may 
eventually contribute to the development of an 
efficacious vaccine).
• What benefits are not allowed? For example, 
there are prohibitions on developing or testing 
offensive weapons, testing alcohol or tobacco 
products and testing cosmetics. (Ibid)
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The ASRU HBA note further explains (p19) that 
benefits are qualitatively weighted8 within HBA 
to reflect their likely value, including in terms of:
• the seriousness of a human disease
• the number of patients affected
• the overall societal impact
• filling a knowledge gap in basic science 
• regulatory requirements 
Benefits are also qualitatively weighted within 
HBA to reflect their likely success. These reflect: 
• the clarity of objectives
• the research establishment’s track record
• the provision of detailed information
• the application of the 3Rs (ibid, p20) 
The weighing of harms against benefits is then 
carried out. This is the process of determining 
if the overall harm that will occur is justified by 
the benefits that are likely to be delivered. 
The HBA advice note acknowledgest that 
inspectors are required to make value-laden 
judgements (ibid, p17), but advises that these 
judgements are expected to be balanced, 
rational and consistent across project licence 
applications (p19) and based on the information 
provided in the application and other relevant 
sources. The HBA advice note outlines that 
ASRU makes use of referrals, the scientific 
literature and discussion to evaluate benefits 
fully and consistently. 
Nevertheless, there remain multiple sources 
of uncertainty in evaluating benefits, from the 
inherently open-ended nature of scientific 
research, to the variability of value accorded to 
different kinds of benefit. In addition, in-depth 
personal knowledge about the science relating to 
each project application and access to the relevant 
scientific literature, may not always be available 
to individual ASRU inspectors and it is not clear 
how much time and resource is available for such 
consultation. 
8  The ASRU (2015) HBA advice note uses the specific local terminology of weighting benefits to refer to the likelihood and value of those benefits 
and weighing to reflect the way that they are balanced against harms. This report uses the ASRU terminology of weighing in the same way, but 
uses the more general terms of assessing or evaluating benefits instead of weighting benefits. 
For these reasons, much rests on whether the 
scientists’ claims about the potential benefits 
in project applications are clear and persuasive 
(ibid, p20), 
and whether there is trust and confidence 
in their establishments’ cultures of care 
and capacity to support delivery of the promised 
benefits. Other research also suggests that 
confidence, rather than evidence may be key 
to the authorisation of animal experiments (Vogt et 
al., 2016). 
4.2.2. CHANGING CULTURES 
OF SCIENTIFIC PRACTICE 
The APC review (2003, p29) emphasises that only 
scientifically valid projects should move on to HBA. 
Determination of scientific validity should cover 
factors such as: 
• the validity of the scientific approach
• experimental design 
• statistical analysis 
• choice of animal models 
• experience of the research team in the 
particular field
• sufficiency of resources, including staff time, 
funding and quality of the facilities (see also 
Jennings and Smith, 2015)
All the above assessments should be critically 
evaluated over time, encouraging researchers 
and their AWERBs to “consider whether and how 
far they engage in sufficient innovative, creative, 
flexible and challenging thinking when choosing 
methods and models” (APC, 2003, p80). 
In the period following the APC report, questions 
around research integrity, reliability, reproducibility 
and misconduct have received considerable 
attention from learned societies, most recently 
in the research integrity inquiry (House of 
Commons Science and Technology Committee, 
2017). These reports have sought to support 
behaviours and values that result in high quality, 
ethical and valuable research concerns and 
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understand the ways in which individual incentives 
and competitive research cultures (for example, 
‘publish or perish’ demands) may impede the 
realisation of good practice. 
Researchers’ career progressions and economic 
benefits9 are not permissible purposes under 
the A(SP)A. They are indirect outcomes of a 
successful project authorised under one of 
the permissible research purposes, rather 
than benefits in their own right. Nevertheless, 
it is important to recognise that research and 
credit structures in science have become more 
competitive and commercialised in general. 
These motivations for carrying out animal research 
and testing cannot be critically evaluated as part 
of the full assessments of benefits. However, 
these aspects of research culture have contributed 
to concerns about research practice and integrity, 
so it is important to be aware of how they may 
shape the experimental practices, publishing 
behaviours and narratives of potential research 
impact in the HBA. 
As the ASC outlined in its 2017 response to the 
Science and Technology Committee consultation 
on Research Integrity (ASC, 2017; see also 
Würbel, 2017), research integrity is an ethical 
consideration fundamental to the realisation of the 
benefits of research using animals and demands 
attention at all levels of the research process from 
individual experiments to institutional factors. 
Research integrity is an ethical 
consideration fundamental to the realisation 
of the benefits of research using animals 
and demands attention at all levels of 
the research process from individual 
experiments to institutional factors.
4.2.3. SPECIFYING 
MEANINGFUL TIMESCALES
While short-term benefits may be measurable, 
medium-term benefits (for example, contributing 
towards a greater understanding of a physiological 
system of interest) and long-term benefits (for 
example, providing information that has led to 
a new therapy for a specific disorder) become 
progressively more difficult to assess. 
9  The HBA advice note (ASRU, 2015, p19) does indicate the economic benefits of a new chemical.
It is not clear how and to what extent longer 
term benefits are considered by the regulator, 
institutions (including AWERBs) or indeed funding 
bodies. The response to the question “When 
will the benefits be achieved?” (ASRU, 2015, see 
4.2.1 above) includes the phrase “decades in the 
future”. Research may have benefits realised over 
these timescales and stating these ambitions 
may help to underline and deliver on project 
objectives. However, the ASC suggests that these 
are currently difficult to evaluate in a rigorous way 
within the prospective HBA of an individual project 
and could be used to signal general aspirations 
rather than likely benefits.
There is now more research retrospectively 
tracking research benefits, which the ASC 
explores below. This includes reporting on 
research completed up to 20 years before ‘impact’ 
is recorded. Whilst it remains difficult to predict 
potential or prospective benefits over these 
timescales, these reports could be used to help 
break down such aspirations into the discrete 
activities and short-term milestones that increase 
accountability and the likelihood of delivering on 
longer term objectives. 
Given that open-ended assertions of benefits can 
potentially be used to justify any procedure on 
animals, the ASC suggests that assertions that 
projects may to lead to long-term gains should 
be carefully scrutinised and not given undue 
weight in the HBA. Given this, the ASC suggests 
that the phrase “decades in the future” is not an 
appropriate terminology to use in the prospective 
evaluation of likely future benefits. The ASC 
would encourage researchers, AWERBs and the 
regulator to focus on identifying the processes 
(and if possible probabilities) that can be used to 
demonstrate and evaluate steps taken towards 
longer term project objectives, including using 
checklists and milestones. 
4.2.4. USING CHECKLISTS, 
INDICATORS AND MILESTONES
As ‘weighing’ is a matter that requires judgement, 
there are no easy-to-follow rules for assessing or 
quantifying when the likely benefits justified the 
overall harms. The HBA advice note describes 
the process of weighing benefits and harms  
as follows: 
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“Having considered the aspects of the harms 
and the benefits in detail, an overall judgement is 
made regarding the severity of the harms and the 
value and likelihood of delivery of the benefits, ie 
both harms and benefits are weighted. In order 
to determine whether or not a project should be 
granted, the harms are then weighed against 
the benefits. The weighing of harms against 
benefits can be considered to be the process 
of determining if the overall harm that will occur 
is justified by the benefits that are likely to be 
delivered. Since there are no agreed quantitative 
units for either harm or benefit, this is not a 
quantitative analysis.” (ibid, p18, point 17.)
However, there are methods available to 
support this process and ensure that HBA is as 
transparent, rigorous and legitimate as possible. 
Many of these have been developed by local 
AWERBs. They include a mix of lists and models, 
as indicated below.
Decision support tools
• Published guidelines: These include: Prentice 
et al., (1990); Smith and Boyd (eds) (1991); de 
Cock Buning and Theunen (1994); Delpire et 
al., (1999); APC (2003); Smith et al., (2007); 
European Commission (2013); Home Office 
(2014, especially Appendix I); Jennings and 
Smith (2015); Laberet al., (2016). 
• Local lists: Many AWERBs will have drawn 
up lists of factors for consideration for 
themselves, to help to guide the evaluation of 
harms and benefits and to offer some insights 
regarding weighing. 
• Visualisations: Bateson’s cube (Bateson, 1986) 
offers a visual guide or heuristic to weighing 
harms and benefits, based on three criteria: 
animal suffering; probability of benefit; and the 
quality of the research. Each are graded as 
‘low’, ‘medium’ or ‘high’. 
• Scoring schemes: (for example, Porter, 
1992; Boisvert and Porter, 1995; Stafleu et 
al., 1999) may offer some insights. However, 
these are not otherwise favoured, as it is widely 
agreed that ethical weighing cannot be a 
quantitative process.
Using such tools can help to ensure that the 
weighing process is as comprehensive as 
possible. They can highlight areas of concern 
that, in turn, can lead to further discussion, 
reflection and negotiation – for example, with 
individual researchers, via the AWERB, with wider 
stakeholders and public and/or in dialogue with 
the Home Office Inspectorate. The outcomes of 
these discussions might be to explore alternatives, 
reduce harms and/or enhance benefits – or in 
some instances, just to say ‘no’. 
Most commonly used are lists of factors that can 
help to identify and assess potential benefits in 
the different stages of the evaluation process. 
These may allow for some rough categorisations 
of possible outcomes – for example, ‘low’, 
‘medium’ or ‘high’ potential benefits. Some 
factors also act as proxies for certain attributes 
of quality in the absence of quantifiable aspects 
of research benefits. 
The HBA advice note includes reference to the list 
of factors and information sources used by ASRU 
to evaluate the range and likelihood of benefits 
(ASRU, 2015, pp16-18). These prompts are used to 
enhance the coverage and consistency of reviews 
across project licences and inspectors. 
Other lists have been developed by individual 
establishments; these can help to ensure that the 
factors are directly relevant to the establishment’s 
own specific areas of animal research. 
Institutional AWERBs play a vital role in discussion, 
assessment and enhancement of benefits. 
They are well placed to consider the impact of 
local, institutional factors such as “access to 
information about the 3Rs, standards of animal 
care and accommodation, management of animal 
use and expertise and competence of staff” on 
the likelihood of achieving benefits (Jennings and 
Smith, 2015).
Many lists focus on the identification of direct 
benefits. This is important, but there is scope to 
consider additional information that is relevant 
to the realisation of benefits and the potential for 
indirect benefits. This might include information 
about the research team’s objectives with respect 
to maximising the benefits of the research, such as 
plans for publications, liaison with other research 
groups (including clinicians, where relevant) and 
public and patient engagement. Commitments to 
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promulgate information about the application of 
the 3Rs and the enhancement of benefits would 
also be helpful, provided that these are realised 
in practice.
Given the growing role and diversity of lists used 
to weigh harms and benefits, there is scope to 
engage in debate with others involved in HBA and 
widen the discussions around the use of these 
checklists and their associated milestones.
Recommendation 14
Researchers and AWERBs should support the 
rigour, transparency and legitimacy of HBA by 
ensuring that research objectives and project 
milestones for realising research benefits are 
realistic, clear and accountable in advance. 
These should be reviewed over the lifetime 
of project licences and opportunities sought 
to enhance benefits. These processes may be 
facilitated by sharing checklists developed by local 
AWERBs and using other appropriate decision 
support tools.
Sometimes the use of proxy indicators, such as 
impact factors to signify project licence applicants’ 
scientific credentials, may be considered in the 
evaluation of benefits. However, the San Francisco 
Declaration on Research Assessment (2013)10 has 
criticised impact factors for being: 
• opaque 
• lacking predictive capabilities 
• contributing to unhelpful publishing behaviours
Debates about research reproducibility and 
integrity have been particularly critical of how 
indicators of research quality, like impact factors, 
may be encouraging grant and publishing 
behaviours in which “no-one is incentivised to be 
right” and where “scientists too often sculpt data 
to fit their preferred theory” (Horton, 2015, p1380). 
The ASC recommends that impact factors are not 
used in HBA as this would unjustifiably accentuate 
their importance.
10   The San Francisco Declaration on Research Assessment (DORA) was initiated in 2012 by the American Society for Cell Biology (ASCB) to 
improve the ways in which the outputs of all scientific research are evaluated. For more information see http://www.ascb.org/dora/ (last 
accessed 22/08/201)
Recommendation 15
Whilst targeted checklists and project-specific 
milestones may be valuable for evaluating the 
likelihood of success for the HBA, key information 
on animal research is often missing from highly 
ranked journals. This suggests that journal impact 
factors should not be used as a proxy for quality 
criteria around the likelihood of success when 
assessing individual project licence applications.
After a project licence has been granted, there 
should be planned, defined and measurable 
milestones to trigger reviews of progress, including 
an ongoing assessment of the likelihood that 
the potential benefits will be achieved and steps 
to ensure that the impacts of the work will be 
maximised. These milestones can apply to short-
term benefits and the interim stages en route 
to medium- and long-term benefits, which are 
otherwise more difficult to predict. 
The potential for additional or longer term benefits 
may also be enhanced if researchers include 
in their milestones appropriate proposals for 
curating, archiving and providing access to their 
research data.
Recommendation 16
Not all benefits can be anticipated in advance, 
but the potential for realising unforeseen and 
additional benefits can be enhanced. Researchers 
and establishments should be encouraged to be 
responsive to opportunities to enhance emerging 
benefits (for example, through cross-project and 
AWERB hub collaborations) and should implement 
the most appropriate proposals for curating, 
archiving and providing access to their research 
data, to inform and enhance long-term benefits.
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4.2.5. DIVERSITY AND REVIEW IN 
HARM-BENEFIT ANALYSIS
The outcomes of the weighing process in HBA 
may vary between projects, as well as between 
Home Office inspectors and across other ethical 
reviews, including AWERBs and the ASC. 
The HBA advice note (ASRU, 2015) suggests 
processes that can help to “ensure that significant 
inconsistency is avoided”, including: 
• referral to inspectors with specialist expertise 
• use of inspector panels, case discussion 
groups and/or independent assessors 
• referral to the ASC
• engagement with external stakeholders who 
share disparate views 
However, differences of opinion will continue to 
arise and should be expected. AWERBs coming to 
different conclusions around HBA can reasonably 
result from each applying their own unique or 
different ‘local’ perspectives and values. 
For these reasons, HBA should be a dynamic 
ongoing process, not a one-off event (APC, 1997, 
p50, point 1.2) that is re-evaluated at appropriate 
intervals throughout the lifetime of a project, 
from the initial idea through to the publication 
of findings. HBA should take account of any 
changes to the levels of harm, how these might 
be ameliorated and the degree and likelihood of 
benefits being realised. It should also be constantly 
alert to new developments in scientific methods 
and knowledge about animal welfare that could 
be used to alter the balance of likely benefits and 
harms in a project. 
4.3. IMPROVING THE 
EVALUATION AND 
REALISATION OF BENEFITS
All project licences aim to generate worthwhile, 
lasting benefits – whether they relate to: 
• the basic science that might underpin future 
scientific advances
• research directed towards clinical applications
• testing that meets regulatory requirements to 
help to safeguard human and animal health and 
the environment 
Applicants for a licence to use animals in research 
are asked to identify these proposed benefits 
when filling in the project licence application 
Sometimes, animal-based studies lead to direct, 
highly beneficial outcomes – but more often the 
benefits are indirect, in that they form a small part 
of a jigsaw of scientific findings that together might 
contribute to a breakthrough.
Here, the ASC discusses ways in which the 
realisation of hoped-for benefits can be supported 
and facilitated through: 
• systematic review 
• experimental design 
• translational research 
• regulatory testing 
Not all these steps will be relevant to all projects 
and some efforts to assess the pathways to 
benefits are still in the early stages of development. 
However, engagement with these will help to 
embed review and learning across the processes 
of HBA. 
4.3.1. SYSTEMATICALLY 
REVIEWING CURRENT EVIDENCE 
In establishing the potential for benefit, it is 
important to review the current evidence 
base before deciding if animal use is justified. 
This can prevent the unnecessary use of animals, 
for instance:
• where there is already sufficient evidence to 
support scientific claims and replication is 
not necessary
• where there is clear evidence that an approach 
will not work
The current ‘gold standard’ approach to reviewing 
existing scientific evidence is a systematic review of 
the published literature followed by meta-analysis, 
if feasible, of the relevant studies. A systematic 
review is used to identify all relevant published 
literature by searching appropriate databases. 
These are then filtered to identify the papers that 
are relevant and contain evidence of acceptable 
quality. Subsequent meta-analysis of the relevant 
papers can be used to assess the quality of 
evidence in a research area and to identify potential 
issues with the evidence-base, such as publication 
bias, which may skew the results.
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Together, these methods can help to ensure 
that a researcher’s choice of animal methods is 
appropriate and capable of yielding the anticipated 
benefits (Hooijmans and Ritskes-Hoitinga, 2013; 
van Luijk et al., 2014) and that the licensing 
decisions are fully informed. 
A range of tools is now available (as at August 
2017) to facilitate the performance of systematic 
reviews of animal studies and subsequent meta-
analysis. A selection of these are listed below 
(links were active in August 2017).
• CAMARADES-NC3Rs Preclinical Systematic 
Review & Meta-analysis Facility (SyRF)  
http://syrf.org.uk/
• SYstematic Review Center for Laboratory 
animal Experimentation (SYRCLE) 
https://www.radboudumc.nl/en/research/
technology-centers/animal-research-facility/
systematic-review-center-for-laboratory-animal-
experimentation
• Canadian Council on Animal Care 
http://3rs.ccac.ca/en/research/systematic-
reviews.html
• The Critical Appraisal Skills Programme (CASP) 
checklist 
http://www.casp-uk.net/casp-tools-checklists 
Recommendation 17
An explanation of the potential benefits of animal 
research in the project licence is justified through 
locating the research in the current relevant 
field and knowledge. As techniques become 
more refined and widely available, researchers 
are encouraged to supplement these with 
relevant reference to tools for systematic review 
and meta-analysis. 
The systematic improvement of and learning from 
the outcomes of animal research requires the 
publication of valid data from the range of animal 
studies carried out, whether or not they support 
the original research hypothesis. The value of a 
systematic review of evidence requires that the 
published literature is an accurate representation 
of the current knowledge base.
11  http://www.rcuk.ac.uk/media/news/150415/ (last accessed 23/08/2017)
HBA for animal research is also ethically 
problematic if data are not made available, 
as animals harmed in unpublished research 
cannot contribute potential benefits. 
HBA for animal research is also ethically 
problematic if data are not made available, 
as animals harmed in unpublished research 
cannot contribute potential benefits. 
Recommendation 18
Researchers should strive to publish all the valid 
data that have resulted from animal research in an 
appropriate and accessible format, whether  
or not they support the original hypothesis.
4.3.2. ENSURING RESEARCH INTEGRITY 
AND GOOD EXPERIMENTAL DESIGN
The ASC considers that ‘research integrity’ 
includes ensuring that research using animals 
both seeks to minimise harm and maximise 
benefit (ASC, 2017). The realisation of any 
potentially beneficial data from animal research 
depends upon good experimental design, suitable 
experimental practice and valid statistical analysis. 
This is the shared responsibility of funders, 
researchers, professional societies, AWERBs, 
establishment licence holders and inspectors. 
Ensuring research integrity and good experimental 
design is an ongoing area of strategic discussion 
across the animal research and biomedical 
research community. It is a particular challenge 
in universities, where research may be diverse 
and expertise widely distributed. Funders, 
publishers and educators all have a role to play 
in supporting the development and promulgation 
of good practice. There is currently (August 2017) 
considerable attention being paid to this issue. 
The Research Council UK (RCUK) has updated its 
online guidance for funding applications involving 
animal research in 201511. This now requires 
that: “All proposals using animals should explain 
not only the need to use animals and the ethical 
implications of the planned experiments, but also 
clearly describe how the planned experimental 
design is appropriate to give robust results.”
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The review of investments in in vivo education 
via the British Pharmacological Society (BPS) 
(Lowe et al., 2016) outlines the value of roles 
like the ‘experimental officer’ – a centrally 
supported source of advice and review for 
experimental design and data analysis. The BPS 
has commenced working with educators and 
employers in the in vivo community to develop 
clear core learning objectives, including around 
experimental design, statistics, animal welfare, 
cultures of care, ethics and the 3Rs. 
The Animal Research: Reporting of In Vivo 
Experiments (ARRIVE) guidelines (Kilkenny et 
al., 2010) were developed in consultation with 
the scientific community to improve standards 
of reporting of research using animals. They are 
intended to improve the reporting of experiments, 
ensure key information about the use of 
animals in studies are available and minimise 
unnecessary research. 
However, the 2016/17 consultation on research 
integrity (House of Commons Science and 
Technology Committee (2017)), the identification 
of inadequate methodologies used in animal 
research (Bara and Joffe, 2014) and the continued 
gaps in reporting of animal research (Macleod et 
al., 2015; Carbone and Austin, 2016) suggest that 
there are still considerable improvements required 
in experimental practice and the evaluation of 
experimental design and statistical power to realise 
the benefits proposed in the HBA.
Benefits from all research will be enhanced by 
further critical attention to the following elements 
of HBA: 
• the validity of the procedure as a means of 
fulfilling the research objectives 
• the rigour of the experimental design 
• the statistical validity of the number of  
animals used 
• the reliability of experimental findings 
• the planned reporting of research practice 
and outcomes 
The demonstration of benefit might reasonably 
be judged not against achieving an arbitrary level 
of statistical significance but rather a strength of 
evidence (a positive predictive value) reached after 
the completion of the experiment. This allows 
users of research to have certainty in the findings 
presented (Mogil and Macleod, 2017).
There are now resources available to researchers, 
AWERBs and others to assist in the development 
of appropriate experimental design and reporting 
of data. Current tools (with links active in August 
2017) include:
• The NC3Rs Experimental Design Assistant – 
https://www.nc3rs.org.uk/experimental-design-
assistant-eda 
• The NC3Rs ARRIVE (Animal Research: 
Reporting of In Vivo Experiments) guidelines  
– https://www.nc3rs.org.uk/arrive-guidelines 
 
Recommendation 19
Researchers, establishments, AWERBs, 
funders and regulators should work to support 
researchers in meeting current quality criteria 
for experimental design and reporting relevant 
to their disciplinary area. This should include 
facilitating informed discussions around methods 
for selecting appropriate sample size, mitigating 
bias, incorporating randomisation and the blinding 
of outcomes.
4.3.3. IDENTIFYING BENEFITS FROM 
ORIENTED BASIC RESEARCH 
As for all research and testing involving animals, 
basic or fundamental research must be deemed 
sufficiently important and necessary to justify the 
use of animal procedures. The potential benefits 
of the work must be weighed against the harms 
caused to the animals; to achieve a positive HBA 
outcome, there must be an appropriate balance 
between the two.
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There are additional challenges in evaluating the 
benefits from basic research. In part, this reflects 
the specialised nature of the potential benefits 
from basic research, which need to be specified 
in the HBA12, but may be less accessible to and/
or accepted by the range of perspectives around 
animal research. It also reflects the changing 
position and definition of basic research itself13. 
Much research can be placed on a spectrum that 
spans from basic to applied research; with basic 
research always being conceived with a strategic 
research development in mind. Researchers are 
increasingly encouraged to present their work 
to funders in ways that highlight its translational 
nature and potential benefits, so applications that 
may have been seen as basic in the past are now 
identified as both basic and translational research. 
There are dangers in both overstating translational 
research applications (in exaggerating research 
and raising unrealistic expectations, resulting in 
an inappropriate HBA) and in undermining the 
potential benefits of more basic research (in not 
identifying and engaging other potential research 
users and communities to realise benefits). 
It is essential for the proposed benefits to be 
transparently and honestly set out for all research 
and to recognise that there may be implications 
for the HBA if the potential benefits change along 
the spectrum between basic and applied as 
research develops. 
The OECD (2013) defines basic research as 
“experimental or theoretical work undertaken 
primarily to acquire new knowledge of the 
underlying foundations of phenomena and 
observable facts, without any particular application 
or use in view” [ASC’s emphasis]. The ASC views 
the OECD (2013) definition of oriented basic 
research as a more accurate and appropriate 
characterisation of most contemporary animal 
research. This is defined as “research carried out 
with the expectation that it will produce a broad 
base of knowledge likely to form the background 
to the solution of recognised or expected current 
or future problems or possibilities”. 
12   Whilst it can be argued there is always the potential for a piece of research to lead, directly or indirectly, to human or veterinary or   
environmental benefits, such a claim is so broad as to be meaningless for the HBA.
13   Calvert and Martin (2001) suggest that there is no clear-cut boundary between basic and applied science. Moreover, they show how the 
definition of basic research has changed historically and is more often used as a marker of intention rather than an accurate description of 
scientific practice. They outline how the idea of ‘basic science’ developed alongside the growing involvement of the military and industry in 
science. Basic science was used in the post-war period to identify an ethical ideal of science furthering knowledge for its own sake and a 
particular type of scientist who was autonomous and curiosity-driven. The subsequent shift to so-called Mode 2 knowledge production, has 
seen a return to science that is valued for being context-driven, problem-focused and interdisciplinary (Gibbons et al., 1994).
This definition recognises the indistinct boundary 
between basic and applied research and 
acknowledges the expectation (whether realised 
or not) that knowledge gained through the 
research may support future advances that could 
help bring benefits to humans, animals and/or 
the environment. Recognising the oriented basic 
nature of most contemporary research should help 
to subject studies to appropriate HBA at the outset 
and to review these as research develops. 
In the ASC’s view, the likelihood that a piece of 
research could lead, directly or indirectly, to human 
or veterinary medical and/or environmental benefit 
can have a bearing on the level of harm that is 
deemed permissible. 
In the ASC’s view, the likelihood that a 
piece of research could lead, directly or 
indirectly, to human or veterinary medical 
and/or environmental benefit can have a 
bearing on the level of harm that is deemed 
permissible. 
For example, if a study that is initially presented as 
likely to be translatable soon is discussed in depth 
and, as a result, is ‘reclassified’ as being further 
away from likely application (and angled towards 
basic research), the level of harm that would be 
acceptable to achieve the scientific objectives may 
well be reduced, directly impacting on HBA. 
Here the ASC restates the applicability of 
recommendation 14 for all oriented basic research 
and translational research. 
4.3.4. DEVELOPING PATHWAYS FOR 
TRANSLATION OF RESEARCH 
In recent years funding bodies and policymakers 
have invested considerable resources to support 
the translation of laboratory animal research into 
clinical applications for human and animal health. 
Early policy identified different stages of research, 
from bench to clinic, to help to understand 
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barriers to translation (see, for example, Khoury 
et al., 2007; Westfall et al., 2007; Dougherty and 
Conway, 2008). 
At the same time, work mapping the complexity 
of networks involved in translation (Cambrosio 
et al., 2006) demonstrated the nonlinear nature 
of much translational research and the value 
of interactions between laboratory researchers 
and clinicians (Fudge et al., 2016). Recognition 
of the complexity of the process of translating 
research from the laboratory to clinical application 
is an important counter to the linear and at times 
overstated claims made about the likely benefits 
of single projects. 
Preclinical research (animal) and clinical 
applications (for both human and animal) can 
sometimes vary widely and the extent to which 
researchers liaise to understand clinical contexts 
or commercial viability is not always evident. 
More opportunities for dialogue between basic 
and clinical scientists can facilitate and enhance 
this process – especially when laboratory 
researchers are able to work alongside clinicians 
and others at an early stage in the research 
process. This may enable the better alignment of 
animal models and clinical contexts – and, later, 
the publication of findings in journals that are read 
by clinical communities or the engagement of 
commercial developers. 
To assist inspectors and others involved in the 
evaluation of research benefits, the ASC has 
drawn on analysis of the REF2014 Impact Case 
Studies.14 These case studies report the impacts 
of biomedical research carried out in UK higher 
education institutions (HEIs). 
The analysis covers six main pathways through 
which research in HEIs is judged to have a 
demonstrable impact on human and veterinary 
medicine through: 
• Drug discovery and development 
• Implementing platform technologies 
• Developing translational devices 
• Breakthroughs in experimental medicine 
• Changing health and welfare practices 
14  This currently unpublished research was carried out by Professor Gail Davies and Gabrielle King at University of Exeter in 2016 for the purposes 
of this report. All links to REF2014 case studies last accessed 8/9/2017.
• Informing public debate and policy
These are elaborated and illustrated with active 
links to case studies in Table 4; the methods are 
explained in Appendix D.
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The case studies do have limitations in the context 
of HBA, but serve to illustrate how reported 
impacts are being linked to specific scientific 
studies in retrospective accounts. Characterising 
how the different routes that have delivered 
research impact in the past should provide 
insights to help to enhance the benefits of future 
research efforts. 
The examples are not exclusive or exhaustive, 
but the case studies do indicate how different 
pathways to translation involve collaborations 
with distinctive groups of clinicians, policymakers, 
or spin-off companies and are organised around 
particular technologies, such as biomarkers, 
translational devices, or standardised platforms. 
Identifying these pathways can help to clarify 
what might make a ‘persuasive argument’ about 
benefits in different kinds of project licence 
applications, as well as being used to offer specific 
guidance on the realisation of research benefits 
once a licence has been granted. 
The analysis also suggests that different 
pathways raise distinctive challenges for HBA, 
with Table 4 reflecting on how these challenges 
might be overcome and where additional scrutiny 
may be required.
Recommendation 20
Assessment of the benefits from translational 
research would be enhanced by researchers 
defining measurable translational research 
objectives . These should operate within the scope 
of the specific project and provide evidence of 
their ability to access appropriate pathways to 
translation in that area (for example, via clinical 
collaborations, data exchange, publishing plans, 
policy engagement and commercial partnerships). 
The reporting and monitoring of research impacts 
has the potential to improve project-specific claims 
made by researchers about the benefits of animal 
research and the ASC encourages inspectors and 
AWERBs to explore these resources now. 
15  http://www.hefce.ac.uk/rsrch/refconsultation/ (last accessed 16/8/2017)
Recommendation 21
Researchers, AWERBs and ASRU inspectors 
are encouraged to search the publicly accessible 
REF impact case studies for past examples in 
fields related to new applications in translational 
research. The current case studies have 
limitations, but do provide an overview of 
translational pathways in different fields. As data 
returned improve and new techniques for 
interrogating the case studies provide enhanced 
responses to queries, this database will increase 
its potential to inform the HBA process.
The ASC has responded to the 2017 REF 
consultation15 with recommendations for enhancing 
the data collected on animal research in future 
research assessments to assist this review of 
benefits and help improve HBA in the future. 
Recommendation 22
Future Higher Education Funding Council 
for England (HEFCE) evaluations of research 
impact should include a mandatory and 
consistent reporting framework for animal use, 
commensurate with its status as research that 
requires a special ‘social’ licence to operate. 
This would enable better analysis of the impacts 
of research using animals and help regulators to 
improve future HBAs for animal research. 
4.3.5. COLLABORATIVELY EVALUATING 
BENEFITS IN REGULATORY TESTING
Regulatory procedures are performed to satisfy 
legal requirements for licensing potentially 
profitable substances and products, including 
medicinal products for human use, veterinary 
products, medical devices, industrial chemicals, 
biocides and in relation to food safety. Regulatory 
science usually requires standardised protocols, 
which aim to determine whether and how far 
such substances and products are sufficiently 
efficacious and safe for approval for use and 
marketing. A unique aspect of animal studies 
conducted for safety is that their primary purpose 
is to identify potential hazards for humans, or 
the environment, which means they focus on 
establishing the nature and scope of adverse 
effects in animals. 
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According to Home Office (2016) statistics 
regulatory procedures are primarily performed for 
the purposes of: 
• toxicity and other safety testing including safety 
pharmacology 
• the production of products, for example, blood-
based products 
• quality control, for example, batch safety and 
potency of vaccines 
• pyrogenicity testing 
• ‘other efficacy and tolerance testing’ 
The Home Office statistics (ibid) report that 
555,720 procedures were conducted for 
regulatory purposes in the UK in 2015. Of these: 
• 51,022 (9%) were categorised as sub-threshold 
or non-recovery 
• 322,669 (58%) were mild 
• 93,991 (17%) were moderate 
• 88,038 (16%) were severe 
Four regulatory procedures are listed as triggering 
mandatory referral to the ASRU Regulatory 
Toxicology Group. These are: 
• non-standard acute oral tests 
• skin corrosivity or phototoxicity tests
• non-local lymph node assay skin sensitivity 
tests (using the guinea pig assay) 
• non-standard eye irritancy tests
The percentage of procedures categorised as 
severe for regulatory purposes is higher than for 
other research purposes (see Table 3). 
Researchers, AWERBs and inspectors are 
required to minimise the harms of animal 
tests carried out for regulatory purposes
Researchers, AWERBs and inspectors are 
required to minimise the harms of animal tests 
carried out for regulatory purposes; yet, their focus 
on adverse effects means they remain a significant 
contributor to overall harms experienced by 
animals in research and testing. 
The anticipated benefits from regulatory purposes 
thus require careful and continuous scrutiny. 
However, the benefits from regulatory science are 
specified through tests or data requirements set 
by regulatory authorities. Evaluating the validity 
and acceptability of these benefits involves 
considerations that are beyond the HBA of an 
individual project licence application. Changing 
mandated tests for generating safety and efficacy 
data requires collaboration across research, 
industry and the wider regulatory frameworks for 
product development in the UK and overseas. 
The APC outlined the difficulties of evaluating 
the benefits from regulatory science in 2003. 
It argued that, “there is an element of circularity 
in arguments about where responsibility for the 
scientific appropriateness of animal tests carried 
out for regulatory purposes actually lies, which 
is difficult to break. […] Although regulatory 
authorities should be open to negotiation so 
that only the most scientifically appropriate 
and necessary tests are carried out, it is not 
easy to challenge the requirements laid out in 
the regulations. Regulatory authorities do have 
a role in [harm-]benefit assessment of animal 
procedures and need to allow scientists flexibility 
of approach to ensure that only the most valid 
and vital animal tests are carried out. By the same 
token, toxicologists for their part have a duty to 
continue critically to evaluate the appropriateness 
of the animal tests they perform and to raise 
questions and concerns with the regulators.” 
(APC, 2003, p31). 
Since 2003, there have been significant 
investments in replacements for animals, 
where possible, alongside refining techniques 
and endpoints to reduce suffering. There are 
organisations focused on developing and 
validating alternatives (for example, Johns Hopkins 
University’s Center for Alternatives to Animal 
Testing and the European Union Reference 
Laboratory for alternatives to animal testing), 
as well as bodies working through programmes 
and partnership to promote the 3Rs in regulatory 
safety and industry (for example, The National 
Centre for Replacement, Refinement, and 
Reduction of Animals in Research (NC3Rs) 
and the European Partnership for Alternative 
Approaches to Animal Testing). 
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There have also been collaborative developments 
in the evaluation of valid and acceptable benefits of 
regulatory testing since 2003. These demonstrate 
where change has been possible, including 
through the HBA.
• The International Council for Harmonisation of 
Technical Requirements for Pharmaceuticals 
for Human Use (ICH) has introduced more 
flexible approaches to safety assessment, 
openly promoting the application of the 3Rs 
and removing the requirement for acute toxicity 
testing from the guidelines in 2009. 
• The European chemical testing legislation, 
known as REACH (Registration, Evaluation 
and Authorisation of Chemicals), which 
came into effect in June 2007, included 
amendments around mandatory data sharing 
and the promotion of non-animal test methods, 
including weight of evidence approaches.
• The Home Office has implemented a qualified 
ban on the testing of ingredients that are 
primarily intended for use in household 
products from 2015. This ban was not made 
by legislation but by amending the conditions 
on existing project licences through the HBA 
process (Home Office, 2015a). 
• The European Directorate for the Quality of 
Medicines (EDQM) is active in developing 
alternative approaches to the use of animals, 
with new guidance on tests for vaccine 
development in 2016.16
• The regulatory framework in other sectors 
(for example, food) also allows for tiered 
approaches to testing or approaches such  
as weight of evidence that both minimise  
animal use.
The ASC suggests that there are four 
issues around the definition of benefits from 
regulatory procedures, which are the focus of 
ongoing research and debate and require further 
collaborative endeavour.
16  https://www.edqm.eu/sites/default/files/press_release_pheur_commission_session_3rs_2016_11_22_24.pdf (last accessed 21/08/2017)
17   Many regulators, including the UK's Medicines and Healthcare Products Regulatory Agency (MHRA), require all medicines for humans and 
animals to be tested on two species of animals, one rodent and one non-rodent, in order to ensure patient safety. Commonly used non-rodent 
species include dogs, pigs and monkeys.
• Animal tests are used to assess the safety 
of substances that have differing kinds 
of human benefit and levels of societal 
support (for example, medicines, chemicals, 
pesticides and food additives). For example, 
the HBA advice note (ASRU, 2015) cites 
toxicological safety testing as an example 
of a benefit achieved within the lifespan of 
the project licence. However, this does not 
include consideration of the value to society of 
the substance being tested and whether the 
benefits of a new food colouring are given equal 
weighting to those of a more environmentally 
friendly pesticide, or a pharmaceutical to treat 
a debilitating condition. There are exceptions to 
this, with bans on cosmetic testing (since 1998) 
and the testing of household products (since 
2015), which do appear to make distinctions 
for this purpose (Home Office, 2015a). There is 
scope to make the processes by which such 
distinctions may be made and bought into the 
HBA more transparent.
• There is still ongoing debate about the scientific 
validity and recognition of the limitations of 
animal tests (APC, 2002; APC, 2003; Nuffield 
Council on Bioethics, 2005). Considerable efforts 
are being made to replace animals in regulatory 
procedures (National Research Council, 2007; 
Spielmann, 2012; Bowes et al., 2013). Some 
specific animal tests have been and/or are 
being challenged with respect to necessity, 
for example, acute toxicity studies in the 
development of new medicines (Chapman and 
Robinson, 2007; Chapman et al., 2010). These 
issues around the scientific validity of animal 
research and testing are not unique to regulatory 
science, but given animal tests are mandated 
by regulators as part of safety protocols they do 
require continuing challenge and review.
• The medical sectors are required to use two 
species for safety assessment studies and 
the use of a second non-rodent species17 
raises additional ethical and societal concerns. 
The scientific value of a second, non-rodent 
species is also the subject of debate (APC, 
2002; Smith et al., 2007; Bailey et al., 2013; 
Horner et al., 2013). The NC3Rs is working with 
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the Association of the British Pharmaceutical 
Industry to review the use of ‘non-rodent’ as 
standard practice. This focuses on sharing data 
across industry to evaluate whether standard 
testing paradigms can be modified and 
asking whether data from one species could 
be sufficient for the progression of a potential 
new drug into human clinical trials18. Many 
regulatory toxicology tests were introduced 30 
or 40 years ago. The pharmaceutical industry 
has changed considerably since with new drug 
targets, new types of compounds and new 
in vitro and in silico technologies available to 
evaluate safety. This challenge to requirements 
laid out in the regulations is an important part 
of ongoing HBAs. 
• Some regulatory procedures are conducted in 
the UK solely to satisfy non-EU regulations. 
Most regulatory procedures on animals in the 
UK are carried out in accordance with UK/
EU legislative requirements; according to the 
statistics 97% of regulatory procedures in the 
UK during 2015 were undertaken to satisfy 
this legislation (Home Office, 2016). Very few 
(less than 0.5%) were for UK requirements 
only. However, animals are still being used in 
regulatory toxicology procedures in the UK to 
fulfil non-EU legislative requirements. During 
2015, 19,000 procedures (3%) were to satisfy 
non-EU requirements only (Home Office, 
2016), in contravention of Article 13 of Directive 
2010/63/EU. There are different views here 
that require wider debate. For some, carrying 
out procedures to enable substances or 
products to be marketed outside the EU calls 
into question the justification for causing these 
harms to animals. For others, there is a counter 
argument that these tests are best done in 
the UK where standards of animal care and 
science may be higher. 
Given that the specific benefits from regulatory 
animal research are dependent on the 
requirements for tests and data set by regulators, 
answering these critical issues requires 
collaborative approaches between industry and 
regulators, as well as wider engagement with 
societal concerns around the acceptability of 
different types of benefits (see Chapter 5).23
18  See: https://www.nc3rs.org.uk/news/launch-new-nc3rs-abpi-collaboration (last accessed 8/9/2017)
Recommendation 23
Local AWERBs of establishments engaged 
in regulatory toxicology testing should ensure 
that their mechanisms for weighing harms and 
benefits consider the context of the types and 
utility of substances/products being tested, the 
opportunities for data sharing and the contribution 
to ongoing HBA review in this area of work.
4.4. CONCLUSIONS
There is scope to broaden the resources 
used by researchers, AWERBs and in ASRU 
to assess benefits and to make judgements 
when weighing harms and benefits.
There is scope to broaden the resources used 
by researchers, AWERBs and in ASRU to assess 
benefits and to make judgements when weighing 
harms and benefits. 
There is now more information available 
for evaluating and enhancing the value of 
animal research from work on systematic 
review, experimental design, research impact 
and changes to regulatory requirements. 
This review has sought to introduce, summarise 
and indicate how these resources might be used 
to inform HBA. 
In concluding, the ASC supports further use 
of these resources to develop the criteria and 
checklists for assessing benefits that are available 
to those involved in HBA, including the HBA advice 
note (ASRU, 2015). Existing criteria for assessing 
benefits might be augmented by checking 
whether new resources have been consulted 
and asking additional questions that encourage 
the maximisation of benefits. The ASC suggest 
existing checklists could be supplemented by 
adding questions from the list of issues raised in 
this review. 
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• Has the review of prior work included a 
systematic review of past animal studies?
• Has the researcher employed the experimental 
design assistant, or other tools, to calculate and 
demonstrate appropriate statistical power?
• Are methods of randomisation and blinding 
(masking information about a test from 
participants until outcome are known) 
appropriate to remove bias? 
• Are researchers aware of and compliant 
with Animal Research: Reporting of In Vivo 
Experiments (ARRIVE) guidelines in past and 
planned publications?
• Is the research clear about how it is oriented 
on the basic/applied spectrum and open to 
review if research changes? Are the intended 
benefits from oriented basic research 
appropriately explained?
• Do researchers demonstrate the potential 
to interact effectively and responsively with 
research users in instances of translational 
research (for example, clinical contexts, 
policy communities, learned societies and 
commercial outlets)?
• Is regulatory research clear and transparent 
about the specific direct benefits (for example, 
marketing and licensing)? Are licensing 
requirements mandatory or is there flexibility 
and alternative routes for development of 
the work? 
• Do all researchers indicate how new 
opportunities to recognise and disseminate 
benefits may be identified and enhanced 
during and after the research? 
• Do research programmes identify the potential 
to deliver wider benefits (for example, sharing 
good practices in the 3Rs, new data sharing 
opportunities)?
• Are proposals for gathering, archiving and 
providing access to research data adequate 
and appropriate? 
• Do publication plans include the intention to 
publish all valid results from the study?
• Does animal research that involves known or 
likely societal concerns include the opportunity 
to engage broader social perspectives in and 
through this work? (see Chapter 5)
These questions have the capacity to enhance 
the review of benefits and ensure that benefits 
are more accurately and effectively weighed 
against harms. However, some uncertainty around 
benefits will always remain due to the temporal lag 
between the assessment and delivery of benefits 
and the fact that new areas of uncertainty also 
emerge as knowledge advances. 
The ASC suggests that these enduring 
uncertainties should be acknowledged and used 
to enhance open and transparent debate about 
the practices and potential benefits of animal 
research. Opening up discussion around the 
anticipation of and evidence for benefits has the 
potential to contribute to ongoing reviews and 
improvements of HBA.
UNDERSTANDING 
& INCORPORATING 
SOCIETAL 
CONCERNS
CHAPTER 5
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5. Understanding and 
Incorporating Societal Concerns
5.1. INTRODUCTION
In this final chapter, the Animals in Science 
Committee (ASC) considers how societal 
concerns, including around novel or contentious 
issues, should be factored into the HBA and 
given due weighting. This is important to ensure 
that the UK Animals (Scientific Procedures) Act 
1986 (A(SP)A) is implemented as the public would 
expect. However, it is not known precisely which 
criteria are used to identify applications that 
warrant further scrutiny and how far expectations 
are being met. Greater openness is required 
with respect to these processes, with further 
consideration and initiatives as set out below.
ASRU does identify societal concerns through 
a range of mechanisms that are not specified in 
the HBA advice note (ASRU, 2015). All members 
of ASRU (including the inspectors) represent a 
cross-section of society. They may raise personal 
concerns, making judgements about current 
scientific research and emerging issues from 
science and welfare and decide whether to refer 
applications to the ASC (see Appendix C). It is 
down to ASRU inspectors to decide whether to 
undertake an internal or external referral in relation 
to individual project licence applications. 
ASRU also meets stakeholders from animal 
protection groups and scientific societies on a 
regular, approximately quarterly, basis. This gives 
ASRU the opportunity to hear the wide range 
of views/concerns. Subgroups within ASRU 
also engage in horizon scanning procedures. 
In addition, independent members of Animal 
Welfare and Ethical Review Bodies (AWERBs) 
can provide a valuable perspective from outside 
the research facility, which can give expression 
to public concerns and attitudes, but this is not 
a formal representative role
There is thus scope for the different processes of 
HBA to learn from each other and from emerging 
research on understanding and incorporating 
societal concerns. That said, there are difficulties:
• social scientific work on animal research is 
methodologically diverse and distributed across 
disciplines; it is not always easily accessible and 
can be challenging to compare and evaluate 
• societal concerns are often contextual, 
shifting over time and expressed differently 
in relation to different research contexts and 
forms of enquiries from learned societies, 
review bodies and the social sciences creating 
further problems in integrating data and 
drawing conclusions. 
Despite these difficulties, as outlined earlier, this 
is a critical issue for both science and democracy 
and ongoing dialogue is essential. A range of 
approaches are required to facilitate exchange 
between the scientific community, the regulator, 
interest groups and concerned publics to 
understand the relationship of societal concerns 
to HBA. 
5.2. SOCIETAL CONCERNS 
AROUND HARMS
The list of criteria that the Secretary of State uses 
to refer project licence applications to the ASC for 
advice under A(SP)A Section 9(1) (see Appendix 
C) focuses predominantly on harms. These criteria 
address a mix of concerns about: 
• animal welfare 
• conservation 
• species with which humans have a ‘special 
relationship’ (either because they are viewed 
as companions or because of their cognitive 
capabilities and special requirements) 
• novel, ethical, or societal concerns in general 
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Some of these are well defined and have been set 
out through legislative process (for example, the 
Directive 2010/63/EU ‘safeguard clause’ on the 
use great apes in scientific procedures) or public 
consultation (for example, animals containing 
human material (ACHM)). 
Others are more general, open to definition and 
reflect concerns that go beyond suffering and 
severity. 
It has been tacitly recognised by ASRU in 
the past that some procedures are of special 
concern because of the nature of harms they 
involve. This is borne out by a table, listing 
‘techniques of particular interest’, that appeared 
in the annual Home Office Annual Statistics of 
Scientific Procedures on Living Animals until 2005. 
These were: 
• interference with organs of special sense
• injection into brain
• interference with brain
• psychological stress
• aversive training 
• radiation
• inhalation
• thermal injury 
• physical trauma 
Some of these categories relate to severity, 
although the severity will vary according to the 
way in which the procedures are conducted. 
The ASRU Internal Referral Policy Document 
(ASRU, 2015, Annex C) also lists some referral 
categories that relate to levels of severity, including: 
• severe severity per se
• some toxicology tests
• the ascites method for producing monoclonal 
antibodies 
• the use of strychnine in conscious animals 
However, there is no mention of other sources of 
societal concerns that relate to the assessment of 
harms from proposed animal procedures. 
There is a range of methods for engaging and 
understanding public views on animal research. 
• There are regular large-scale surveys mapping 
broad trends in public opinion, via IPSOS/
MORI in the UK (Clemence and Leaman, 2016) 
and the Eurobarometer in Europe (von Roten, 
2013), enabling review of the different social 
and research characteristics that shape public 
concerns (Ormandy and Schuppli, 2014). 
• There are detailed deliberative processes 
(for example, focus groups, citizen juries and 
consensus conferences) that can be used to 
explore the acceptability of certain harms and 
the desirability of certain benefits (for example, 
Einsiedel 2002; Macnaghten, 2004; see also 
Pound and Blaug, 2016). 
• There are also hybrid analytic-deliberative 
approaches that take citizens through 
structured decision-making processes (for 
example, Deliberative Mapping, Burgess et al., 
2007) or explore how the public make their own 
decisions about the HBA in animal research 
(Lund et al., 2014). 
These differ in approach and outcomes, but 
there are common patterns across them that 
demonstrate: 
• most social concerns about animal research 
are conditional upon the kinds of harms inflicted 
and the nature and delivery of benefits 
• that people do have different views about the 
acceptability of different research species and 
procedures 
• that there are a minority of people who maintain 
strong pro or anti animal research positions 
outside of these contexts
Moreover, qualitative research demonstrates that 
certain social processes recurrently shape societal 
concerns around animal research including:
• people’s everyday experiences of nature 
and animals 
• practices of personal and family caregiving 
(including pets)
• wider social relations of trust with science  
and medicine 
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Societal concerns can emerge from the value 
given to animal integrity and the fact that many 
people get profound enjoyment from animals 
and being in nature and enjoy seeing animals 
healthy and happy in return (Macnaghten, 
2004). People may also have contradictory 
relationships to the animals used in research, 
as they care for both humans and animals in their 
personal lives, whilst having to rely on treatments 
developed through animal research to treat both. 
They may additionally have complex feelings 
about those carrying out and regulating animal 
research, whom they must trust to deliver safe 
and humanely produced medicine, often when 
they are most at need and lacking access to 
relevant information (Davies and Burgess, 2004) 
and even if they have strong personal views on 
animal research. There are thus tangible harms 
caused by high societal concerns around animal 
research, for individuals, for families and for 
the wider relationships around science, medicine 
and democracy. 
What has been explored most extensively in the 
literature are challenges to the integrity of animals, 
especially in relation to suffering or genetic 
modification. The 1995 Banner Report of the 
Committee to Consider the Ethical Implications of 
Emerging Technologies in the Breeding of Farm 
Animals identify deep concerns about “intrinsically 
objectionable” harms that inflict very severe or 
lasting pain on the animals concerned, or involve 
an unacceptable violation of the integrity of a living 
being (Banner, 1995). 
Deep concerns about “intrinsically 
objectionable” harms that inflict very severe 
or lasting pain on the animals concerned, 
or involve an unacceptable violation of the 
integrity of a living being (Banner, 1995). 
For lay people, a perception that an animal’s 
integrity has been violated may well influence their 
perception of what it is acceptable or justifiable to 
do for scientific purposes. 
Examples of societal concerns that relate to 
violating the integrity of the animal include 
procedures that involve interfering with the 
brain or sense organs, or introducing human 
genetic material into brain or reproductive tissue. 
This issue was explored by the Academy of 
Medical Sciences (AMS) within its public dialogue 
on ACHM, which gathered people’s views on 
‘naturalness’, maintaining the integrity of human 
and animal species and their emotional responses 
to different types of experiment (AMS, 2011). 
The Nuffield Council on Bioethics has also 
run a project exploring what people mean by 
‘naturalness’ (Nuffield Council on Bioethics, 2015). 
Terms around naturalness and animal integrity 
are often translated into welfare concerns in the 
practical implementation of regulation. However, 
public consultations do reveal differences between 
expert expectations and lay views around the 
nature of these harms. The AMS reported that one 
concern people expressed related to human-like 
modification of an animal’s external features. From 
purely scientific and animal welfare viewpoints, 
this need not be significant, but the public’s 
view on this was respected when setting out the 
regulatory framework for ACHM. In research on 
xenotransplantation (Davies and Burgess, 2004), 
the public consulted were as concerned about the 
potential allocation of animal and human organs to 
those in need, in ways that reinforced existing lines 
of social inequality, as they were about the ethical 
issues in this proposed new use of animals. These 
processes illustrate how legislation and guidance 
can seek and respect majority public views, even 
when they overspill scientific understandings of 
the harms from animal research and blur the 
boundaries between concerns about animal 
integrity and human dignity. 
There is a range of models for consulting the 
public about animal research, although conducting 
such engagement properly is resource-intensive. 
However, given that societal concerns about 
animal use have significant impacts on social 
experiences and wider social relations of trust, as 
well as being required under the A(SP)A, they do 
need to be researched, considered and respected. 
5.3. SOCIETAL CONCERNS 
AROUND BENEFITS
Just as there are societal concerns relating to 
harms, some purposes and proposed benefits 
are also the subject of debate and controversy 
among the public. Research on societal concerns 
around benefits is more limited and tends to arise 
in relation to specific concerns around particular 
types of benefits. 
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Societal concerns around benefits include 
strong feelings about ‘trivial’ purposes, such as 
cosmetics and household products testing and 
‘socially harmful purposes’, such as alcohol and 
tobacco development. These have led to the 
relevant bans on these specific uses of animals. 
These are widespread societal concerns and 
often still dominate public conversations and social 
imaginations around animal research, even with 
these bans in place. 
The ASRU Internal Referral Policy Document 
(ASRU, 2015, Annex C) lists some referral 
categories that relate to controversial purposes, 
including exposing animals to tobacco smoke 
(as a pharmacological tool to induce diseases 
such as chronic obstructive pulmonary 
disease, not for product development) and the 
development or testing of weapons. These follow 
from prior policy bans, rather than explicit and 
ongoing consideration of societal concerns within  
the HBA. 
In relation to animal research for health benefits, 
there are challenging questions emerging as 
changing societal views about personal health 
responsibility intersect with commercial incentives 
to increase markets for drugs. These concerns 
have often been shaped or channelled by 
campaigning groups, for example, the British 
Union for the Abolition of Vivisection (BUAV) 
argues against experiments to develop Viagra, 
whilst similarly, Animal Aid have campaigned about 
the growing numbers of mice used to test Botox, 
increasingly used for cosmetic purposes. 
Some people have expressed views that animal 
use is not justified in research into other medical 
conditions such as addiction or obesity, because 
they see people affected as ‘to blame’ for their 
condition, although there are strong alternative 
views to this (Lund et al., 2013). Other concerns 
are expressed around the necessity for new 
pharmaceuticals, or other products, in areas 
where there are already many compounds that 
work in very similar ways and the ‘need’ for 
knowledge for its own sake, where this involves 
causing significant animal suffering.
Other more ‘expert’ public, patient and health 
practitioner debate concerns about animal 
experiments with proposed benefits for serious 
human mental health and welfare problems such 
as addiction, anxiety, depression and obsessive-
compulsive disorder are based on validity and 
translatability (for example, Garner, 2014). These 
are controversial issues, with some feeling strongly 
that better animal ‘models’ are essential to help to 
address the relative lack of new pharmaceutical 
treatments in the pipeline, whereas others believe 
that there should be wider debate as to whether 
there should be more effort and investment made 
into ethically conducted social experiments, policy 
change, or non-pharmaceutical measures (Kuyken 
et al., 2015; Alderman et al., 2016). 
Given the diversity of potential benefits, public 
perspectives and methods of engaging the public, 
there will never be a single societal view on the 
benefits of animal research. However, as new 
areas of research increasingly blur the boundaries 
between societal and medical problems and 
increase the level of engagement which patients 
and publics have with animal research, there is a 
pressing need for more regular engagement with 
a diversity of societal views around the appropriate 
benefits of animal research.
As new areas of research increasingly 
blur the boundaries between societal and 
medical problems and increase the level 
of engagement which patients and publics 
have with animal research, there is a 
pressing need for more regular engagement 
with a diversity of societal views around the 
appropriate benefits of animal research. 
5.4. CONCLUSIONS
Attitudes to harm from the use of animals in 
scientific procedures change over time. This can 
and has, led to changes to legislation and 
regulatory requirements in the public interest, 
such as change to legislation in relation to the 
use of great apes.
There are benefits from engaging societal 
concerns in terms of the legitimacy and 
accountability of legislation; there are also clear 
harms in not engaging with genuine public 
concerns about animal integrity, human dignity 
and institutional responsibility.
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There are benefits from engaging societal 
concerns in terms of the legitimacy and 
accountability of legislation; there are 
also clear harms in not engaging with 
genuine public concerns about animal 
integrity, human dignity and institutional 
responsibility. 
At present, societal concerns relevant to harms 
and benefits (along with important ethical 
concerns and novel or contentious issues) are 
not well defined. In addition, there is no clear 
mechanism for ensuring that the diversity of 
relevant issues is identified and given due scrutiny 
within the project evaluation and HBA processes. 
If and when societal concerns are identified, 
they should clearly be placed in the ‘harm’ side 
of the HBA and given due weighting. It should 
be the case that a project that was relatively 
mild, but raised significant societal concerns with 
respect to benefit, would not pass through the 
system without considerable scrutiny, with the 
potential for it not to be licenced.
One way to help to ensure that applications that 
include novel or contentious elements, or that raise 
important ethical or societal concerns, do not slip 
through the net would be to develop guidance for 
AWERBs. This guidance would enable them to: 
• successfully identify such applications 
• apply more stringent local review 
• if they judge that the project can be justified,  
to flag up any concerns to their inspector 
The inspector could then seek additional advice, 
up to and including consulting the ASC.
The ASC recognises the challenges here, in that 
processes are not clearly articulated and evidence 
is difficult to review systematically. The ASC thus 
suggests that a starting point for this work is the 
identification of existing mechanisms for identifying 
societal concerns and further discussion on 
their use and effectiveness by a range of bodies 
involved in HBA. 
Recommendation 24
ASRU currently identifies societal issues through 
personal concerns, knowledge of current debates 
in science and welfare, stakeholder engagement 
and horizon scanning. The specific focus of 
societal concerns will inevitably change over time. 
Reviewing and publishing the working criteria used 
to identify issues as ‘societal concerns’, ‘ethical 
concerns’ and ‘novel or contentious issues’ within 
and across these processes would enhance 
transparency and responsiveness.
 
Recommendation 25
AWERBs and particularly lay members, also 
have responsibility for identifying and addressing 
societal concerns. Building on the ASRU 
experience, there is scope to review the guidance 
produced for AWERBs to help them to identify and 
deal with applications that include elements that 
are novel or contentious, or that raise important 
ethical or societal concerns. 
Recommendation 26
The ASC could usefully review the range of reports 
and mechanisms available to identify societal 
concerns, for example, via AWERB hubs, the 
NC3Rs, the Royal Society for the Prevention of 
Cruelty to Animals (RSPCA) and other ethical 
review bodies. This could be used to develop 
shared understandings of what constitutes 
a societal concern, identify existing public 
engagement and social scientific resources to 
understand these concerns and support HBA in 
better reflecting shifts in prevailing opinions and 
attitudes.
Recommendation 27
There have been a range of public consultations 
on specific issues involving animal research (for 
example, ACHM, household testing) and there 
are regular public surveys through standardised 
questionnaires (for example, IPSOS/MORI). 
However, there is scope to supplement these with 
additional research or stakeholder dialogue on 
the mechanisms through which the public and 
interest groups would themselves identify and 
seek to have societal concerns heard in the HBA 
process (to be sponsored for example, via learned 
societies, science policy groups, or funded social 
science research).
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6. Conclusions and 
Recommendations 
The report concludes by assembling the 
recommendations distributed throughout the 
text on how harm-benefit analysis (HBA) may 
be improved now and into the future. Some 
of these recommendations represent current 
(as at August 2017) good practice already in 
use by some involved in HBA; others present 
opportunities to reflect on and improve existing 
practice.
These recommendations comprise a mix of 
proposals including: 
• those that may be easily achieved through 
changes of practice in the short term 
• those that depend on exchange and learning 
across the different bodies involved in HBA 
and will deliver in the medium term and 
• those that are longer term aspirations 
The ASC has sought to identify potential targets 
for these recommendations below. Given that 
a central aim of this document is to encourage 
mutual learning across all the organisations 
and individuals involved in HBA, the ASC 
invites others to contribute and explore how 
these recommendations can be aligned with 
their ongoing aspirations and initiatives, for 
example, around improving experimental design, 
enhancing reporting in animal research and 
ending severe suffering. 
6.1. ASSESSING HARMS 
EXPERIENCED BY ANIMALS
Recommendation 1: Data on animal welfare, 
including cumulative suffering, should be 
systematically collected in a format that allows 
comparison with other studies of a similar nature. 
Ideally, common reporting standards should 
be developed to facilitate such comparisons, 
for example, through publication, data repositories 
and the AWERB hubs.
Recommendation 2: Realistic estimation of the 
harms likely to be experienced by individual 
animals undergoing licenced procedures is 
critical throughout the different processes of 
HBA. Harms arising from all sources (not just 
procedures, as it is not significant to animals 
where the harms come from) should be taken into 
account by researchers, reflected on by AWERBs 
as part of their responsibilities for the application of 
the 3Rs and considered in the HBA. 
Recommendation 3: Scientists should accept 
their responsibilities to research and obtain expert 
advice on factors affecting the welfare of their 
study species, recognising the impact on science 
as well as animal welfare. Wherever possible 
the HBA should be based on recent scientific 
evidence regarding harms. Where these data are 
not available, efforts should be made to obtain 
data through sharing across organisations, for 
example, via AWERB hubs and identifying priorities 
and funding for future research, for example, 
via the NC3Rs.
Recommendation 4: Retrospective severity 
assessments should be used by researchers, 
AWERBs and the Animals in Science Regulation 
Unit (ASRU) to inform HBAs for future applications 
that employ the same or similar procedures. 
Information gleaned from these assessments 
should offer opportunities for establishment 
AWERBs to reflect on their own retrospective 
severity data and to highlight areas for refinement 
to reduce suffering, whether it be mild, moderate, 
or severe.
6.2. ASSESSING CUMULATIVE 
SUFFERING
Recommendation 5: Consideration should be given 
by researchers, establishments and the regulator 
to the harms experienced over the whole lifetime 
experience of the animal, recognising the risks of 
considering the animal’s experiences in isolation 
and being aware of all potential sources of harm.
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Recommendation 6: Consideration of cumulative 
effects should be used by establishments to 
provide a focus for increasing the animal’s positive 
experiences. Any assumptions about an animal’s 
ability to habituate to procedures, or conversely to 
become sensitised, should be critically scrutinised, 
by researchers, AWERBs and regulator. 
Suggestions that an animal habituates should be 
verified with empirical, objective evidence.
Recommendation 7: Funders, including the 
NC3Rs, should consider further funding research 
into behavioural and physiological indicators of 
cumulative severity and into assessing the affective 
states of animals in research. Researchers should 
explore if this can be done by obtaining valid 
data from animals already undergoing regulated 
procedures, to avoid causing additional harms.
Recommendation 8: AWERBs should be 
encouraged to engage with new research tools 
for recognising and recording cumulative severity. 
These could be used to assist and develop the 
HBA by advising the establishment licence holder 
whether to support project proposals, following 
the development and outcome (retrospective 
review) of projects and providing a forum for 
discussion and development of ethical advice, 
including via AWERB hubs.
6.3. STRATEGIES TO MINIMISE 
SEVERE SUFFERING
Recommendation 9: Researchers and AWERBs 
involved in developing and/or reviewing project 
licence applications prior to submission should 
always provide a robust, constructive challenge 
to the scientific need and the ethical justification 
for using a severe model or procedure. Support 
for this might be provided through additional 
components in existing training for AWERB 
members and exchange via AWERB hubs.
Recommendation 10: Projects that may cause 
severe suffering should be given intensive scrutiny 
at every stage of their design, in the ethical 
review process and in subsequent reporting and 
publishing. This should not only include scrutiny by 
the researchers involved, the AWERB, the Home 
Office inspector and in some cases the ASC – but 
also, where relevant, funding bodies and journal 
editors who publish research involving animals. 
Recommendation 11: Finding new ways of 
working to avoid and eliminate severe suffering 
is a challenge in which every establishment 
and its AWERB should participate. As projects 
progress and at their conclusion, feedback on 
successful refinements and ongoing concerns 
should be provided to all those within and across 
establishments (for example, via AWERBs 
and AWERB hubs) who have been involved in 
addressing severe suffering. The Royal Society 
for the Prevention of Cruelty to Animals (RSPCA) 
Road Map offers a systematic approach and 
opportunity to address questions in the broader 
research community, such as whether severe 
procedures currently in use are necessary and 
whether and by how much a ‘ban’ on severe 
suffering would impact on research and testing.
Recommendation 12: It is important that 
researchers, establishments, AWERBs and 
inspectors all understand that each category of 
severity includes a range of adverse effects and 
that the moderate category includes a particularly 
wide range of procedures, some of which other 
people might regard as severe. Severity categories 
alone are blunt instruments for HBA and at all 
times the likely and actual experiences of the 
animals should be used as the measure of harms 
in the ethical weighing process. There is a legal 
requirement for the project licence holder to notify 
the Secretary of State if the severity limits or 
other controls are, or are likely to be, breached. 
When approaching the upper limit of any severity 
classification, there should be particular scrutiny 
by researchers and establishments of the duration 
of suffering, as long-lasting moderate suffering 
can cross from moderate into severe and similarly, 
long-lasting mild suffering can become moderate.
Recommendation 13: Applicants and AWERBs 
play a key role in driving and implementing change 
and should seek opportunities to improve. ASRU 
already provides feedback to the licence applicant 
following decisions on project licences. There 
should additionally be feedback to and when 
necessary review by, AWERBs when an inspector, 
or the ASC, identifies ethical or welfare concerns 
that the AWERB and the applicant have not 
identified and sought to address.
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6.4. ENHANCING THE 
EVALUATION AND 
REALISATION OF BENEFITS 
Recommendation 14: Researchers and AWERBs 
should support the rigour, transparency and 
legitimacy of HBA by ensuring that research 
objectives and project milestones for realising 
research benefits are realistic, clear and 
accountable in advance. These should be 
reviewed over the lifetime of project licences and 
opportunities sought to enhance benefits. These 
processes may be facilitated by sharing checklists 
developed by local AWERBs and using other 
appropriate decision support tools.
Recommendation 15: Whilst targeted checklists 
and project-specific milestones may be valuable 
for evaluating the likelihood of success for the 
HBA, key information on animal research is often 
missing from highly ranked journals. This suggests 
that journal impact factors should not be used 
as a proxy for quality criteria around the likelihood 
of success when assessing individual project 
licence applications. 
Recommendation 16: Not all benefits can be 
anticipated in advance, but the potential for 
realising unforeseen and additional benefits can 
be enhanced. Researchers and establishments 
should be encouraged to be responsive to 
opportunities to enhance emerging benefits (for 
example, through cross-project and AWERB hub 
collaborations) and should implement the most 
appropriate proposals for curating, archiving and 
providing access to their research data, to inform 
and enhance long-term benefits.
Recommendation 17: An explanation of the 
potential benefits of animal research in the project 
licence is justified through locating the research 
in the current relevant field and knowledge. 
As techniques become more refined and 
widely available, researchers are encouraged to 
supplement these with relevant reference to tools 
for systematic review and meta-analysis. 
Recommendation 18: Researchers should strive 
to publish all the valid data that have resulted from 
animal research in an appropriate and accessible 
format, whether or not they support the original 
hypothesis. 
Recommendation 19: Researchers, 
establishments, AWERBs, funders and 
regulators should work to support researchers 
in meeting current quality criteria for experimental 
design and reporting relevant to their disciplinary 
area. This should include facilitating informed 
discussions around methods for selecting 
appropriate sample size, mitigating bias, 
incorporating randomisation and the blinding 
of outcomes. 
Recommendation 20: Assessment of the 
benefits from translational research would be 
enhanced by researchers defining measurable 
translational research objectives. These should 
operate within the scope of the specific project 
and provide evidence of their ability to access 
appropriate pathways to translation in that area 
(for example, via clinical collaborations, data 
exchange, publishing plans, policy engagement 
and commercial partnerships). 
Recommendation 21: Researchers, AWERBs 
and ASRU inspectors are encouraged to 
search the publicly accessible REF impact 
case studies for past examples in fields related 
to new applications in translational research. 
The current case studies have limitations, but do 
provide an overview of translational pathways 
in different fields. As data returned improve and 
new techniques for interrogating the case studies 
provide enhanced responses to queries, this 
database will increase its potential to inform the 
HBA process.
Recommendation 22: Future Higher Education 
Funding Council for England evaluations of 
research impact should include a mandatory 
and consistent reporting framework for animal 
use, commensurate with its status as research 
that requires a special ‘social’ licence to operate. 
This would enable better analysis of the impacts 
of research using animals and help regulators to 
improve future HBAs for animal research
Recommendation 23: Local AWERBs of 
establishments engaged in regulatory toxicology 
testing should ensure that their mechanisms for 
weighing harms and benefits consider the context 
of the types and utility of substances/products 
being tested, the opportunities for data sharing 
and the contribution to ongoing HBA review in this 
area of work.
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6.5. INCORPORATING 
SOCIETAL CONCERNS 
Recommendation 24: ASRU currently identifies 
societal issues through personal concerns, 
knowledge of current debates in science and 
welfare, stakeholder engagement and horizon 
scanning. The specific focus of societal concerns 
will inevitably change over time. Reviewing and 
publishing the working criteria used to identify 
issues as ‘societal concerns’, ‘ethical concerns’ 
and ‘novel or contentious issues’ within and across 
these processes would enhance transparency and 
responsiveness. 
Recommendation 25: AWERBs and particularly lay 
members, also have responsibility for identifying 
and addressing societal concerns. Building on 
the ASRU experience, there is scope to review 
the guidance produced for AWERBs to help them 
to identify and deal with applications that include 
elements that are novel or contentious, or that 
raise important ethical or societal concerns. 
Recommendation 26: The ASC could usefully 
review the range of reports and mechanisms 
available to identify societal concerns, for example, 
via AWERB hubs, the NC3Rs, the RSPCA and 
other ethical review bodies. This could be used 
to develop shared understandings of what 
constitutes a societal concern, identify existing 
public engagement and social scientific resources 
to understand these concerns and support 
HBA in better reflecting shifts in prevailing opinions 
and attitudes.
Recommendation 27: There have been a range of 
public consultations on specific issues involving 
animal research and there are regular public 
surveys through standardised questionnaires. 
However, there is scope to supplement these with 
additional research or stakeholder dialogue on 
the mechanisms through which the public and 
interest groups would themselves identify and 
seek to have societal concerns heard in the HBA 
process (to be sponsored for example, via learned 
societies, science policy groups, or funded social  
science research).
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Appendix A: Commissioning Letter
Norman Baker MP 
Minister for Crime Prevention 
2 Marsham Street London SW1P 4DF 
 
www.homeoffice.gov.uk
Dr John Landers  
Animals in Science Committee Secretariat  
2 Marsham Street  
London  
SW1P 4DF 
11 August 2014 
 
Dear Dr Landers 
Animals in Science Committee – annual commission
I am writing to you to provide the Animals in Science Committee with a second annual commission of 
work. I would like to take this opportunity to thank you and your colleagues for your achievements to date. 
An important piece of work to which the Committee contributed this year was the publication of the 
Working Protocol between the Home Secretary and the Committee. The document supports the 
provision and receipt of advice and places your independent scientific advice on a firm footing in the 
Home Office. In addition, the Committee recently provided its advice on lessons to be learnt from reviews 
and investigations into non-compliance. This was an important review and I was pleased to accept all of 
the recommendations the Committee made. 
I understand that the Committee proposes to provide reports on its activities on an annual calendar basis. 
Therefore this commission is for the next 18 months to the end of 2015. My commissions for the period 
are as follows. 
Harm-benefit analysis 
The harm-benefit analysis is a cornerstone of our scrutiny process and guides our decision making. I am 
committed to reviewing the analysis that we conduct on all project licence applications. I believe it is 
essential the analysis continues to be robust so we can, with confidence, authorise only that work using 
animals that has a favourable balance of benefit. I therefore include four pieces of work under  
this theme: 
I have asked the Animals in Science Regulation Unit to perform a review of the way in which the harm-
benefit analysis is currently conducted and to prepare a report and guidance which makes this process 
much more transparent. I expect to publish this report in February 2015 and I therefore request the 
Committee to provide advice to ASRU by January 2015 to support this review. 
I have recently received the Committee’s consideration of the Animal Procedures Committee’s report on 
cumulative severity. The report considered the potential lifetime experience of an animal and provided 
recommendations. I will provide a response to the advice shortly. There may, therefore, be further work in 
consideration of cumulative severity as part of a wider review of the harm-benefit test. 
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Building upon the ASRU report mentioned above and your further consideration of cumulative severity, 
I request that the Committee review the current arrangements for performing a harm-benefit analysis. 
The request is three-fold: 
• Advice on current arrangements for performing a harm-benefit analysis and consideration of whether 
this might be improved, 
• Advice that particularly considers the most severe procedures and, relevant to particular types or 
values of benefit, assists in determining where the level of harm lies above which we should not grant 
licences and 
• Advice that reflects on the current process of licence referral (which enables the Committee to perform 
a harm-benefit analysis) and considers how the Committee can maximise the effectiveness of its 
expert scrutiny of such licence applications in a strategic way. 
In the meantime, pending completion of the reviews above, a key element of the Committee’s work 
should continue to be the scrutiny and consideration of project licence applications through the current 
referral process. 
I also commission the Committee to provide advice on the following thematic areas. 
Section 24 
The Home Office has recently completed a public consultation on the review of Section 24 of the Animals 
(Scientific Procedures) Act. Officials will provide the Committee with analysis of the responses arising 
from the public consultation for the Committee’s comment. I would like the Committee to complete its 
review by 19 August so that I may make a public statement about our way forward on our commitment to 
openness and transparency. 
Household Products 
The Coalition has made a commitment to ban the testing of household products on animals. I will 
be proposing a solution which would also effectively end the testing of ingredients primarily intended 
for use in such products unless a strongly justified case can be made for the need to test such an 
ingredient. I will seek the Committee’s advice in the autumn on my preferred policy options with a view 
to implementing the ban by February 2015. 
Code of Practice 
I intend to publish by Christmas this year a revised version of the Animals (Scientific Procedures) Act Code 
of Practice for the care and accommodation of protected animals. Officials will provide the Committee 
with a final draft version for consideration so that I can lay it before Parliament in December. 
Over-breeding 
The Home Office will be reviewing the rationale for high numbers of genetically altered animals bred. 
With advice from the Committee, I would like to identify steps that can be taken to drive down figures 
for genetically altered breeding for publication in February 2015. 
Other functions 
The Committee has a responsibility to engage with Animal Welfare and Ethical Review Bodies. I look 
forward to hearing how the Committee will be taking forward this agenda. 
Yours sincerely
Norman Baker MP Minister of State
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Appendix B: Animals in Science 
Regulation Unit Overview of the 
Application Process
Concept
Draft(s)
Grant
project licence
Refuse
application
AWERB review
Formal application
Formal assessment
Proceed
Proceed
Proceed
Withdraw
Withdraw
Decline
Referral Options
• 2nd inspector
• Inspector panel
• Animals in Science
 Committee
• Independent assessors
Inspector Advice
• Compliance with A(SP)A
• 3RS
Overview of the Application Process
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Appendix C:Referral Processes 
in the Animals in Science 
Regulation Unit Advice Note
The following text is reproduced from pages 12-13 of the Advice note 05/2015: The Harm-Benefit Analysis 
[HBA] Process – New Project Licence Applications (ASRU, 2015)
Referral. 
Where applications raise issues requiring more detailed consideration (e.g. high severity work or other 
matters of particular public concern), additional advice may be sought either by the Inspector or by the 
SoS [Secretary of State]. Applications may be referred within the Inspectorate, to officials or Ministers, 
to independent assessors, or to the ASC [Animals in Science Committee].
viii.  Internal referral within the Inspectorate. An application may be referred to a second Inspector 
or panel of Inspectors if specific expertise is required on an aspect of the application, or if the 
application falls into certain categories. This process is covered by an internal policy document 
(see Annex C). Such referrals can be mandatory or recommended. They either focus on a 
particular aspect of the application (e.g. a protocol that has been classified as severe) or relate to 
the whole application 
ix.  Independent assessor. Advice from an independent assessor may be sought by the SoS when 
the issues raised require specific, expert knowledge not available within ASRU-I [Animals in 
Science Regulation Unit Inspectorate], or when there is debate within the scientific or welfare 
communities, or between the Inspectorate and the applicant about: 
• the scientific validity of the proposed hypothesis(es) to be tested 
• the scientific validity of the proposed methodology 
•  the scope for further application of the 3Rs [replacement, refinement and reduction of the  
use of animals in research] 
• the likely benefits arising from the programme of work 
• the likely harms to animals 
• the choice of species (e.g. is the use of a specially protected species essential?). 
Independent assessors are typically active researchers with relevant expertise. They can be drawn 
from the international research community, or may be UK-based. When the SoS intends to consult an 
independent assessor the applicant is notified, in accordance with Section 9(2) of A(SP)A [the Animals 
(Scientific Procedures) Act 1986] and the SoS will take account of the applicant’s views regarding the 
choice of independent assessor. The applicant is usually told the identity of the independent assessor and 
the questions they have been asked to address. The applicant may also be given the opportunity to read 
the independent assessor’s report. The report may also be made available to the ASC. The assessor’s 
advice will be taken into account in the SoS’s decision, but is not binding.
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ASC. There are a number of criteria that require PPL applications to be referred to the ASC: 
• the use of wild-caught non-human primates (NHPs) 
• the use of cats, dogs, Equidae or NHPs in severe protocols 
• use of endangered species 
• projects with major animal welfare or ethical implications 
•  projects involving the use of admixed embryos falling into Category 3 of the Academy of 
Medical Sciences (AMS) report on animals containing human material (ACHM) and Category 2 
where the predominance of the admixed embryo is unclear or uncertain 
•  projects which may invoke any of the ‘safeguard clauses’ in European Directive 2010/63/EU 
with respect to the purpose of NHP use, proposals for the use of a great ape or proposals to 
cause long-lasting pain, suffering, or distress that cannot be ameliorated 
• projects of any kind raising novel or contentious issues, or giving rise to societal concerns. 
The applicant is always invited to attend the ASC meeting at which the project is considered and is 
given the opportunity to make a presentation about the application. They are also questioned by the 
Committee. The assigned Inspector also attends in order to provide any technical advice that the 
Committee might require. Other Inspectors may also attend. The Committee may recommend to the SoS 
that a PPL be granted (with or without further changes or additional conditions) or that the application be 
refused. Where appropriate, the assigned Inspector discusses the points raised by the Committee with 
the applicant and, if necessary, a final version is produced.
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Appendix D: Analysing 
the Research Excellence 
Framework Impact Case Studies
For the 2014 Research Excellence Framework (REF), higher education institutions submitted a specified 
number of impact case studies. These followed a four-page template, recording the impact of research 
carried out by researchers at that institutions in the 20 years prior to the REF submission date. 
The template included free text sections for: 
• a summary of the impact 
• an explanation of the underpinning research 
• references
• the nature of the impact and supporting evidence 
The impact case studies were submitted to expert review panels for assessment on a four-star scale, 
ranging from 4* research rated outstanding impacts in terms of their reach and significance to 1* research 
impact rated as having only modest impacts in terms of their reach and significance. 
Full information on the REF assessment methodology is available at: http://www.ref.ac.uk/pubs/2011-02/ 
(last accessed 22/08/2017). The searchable database of submitted impact case studies is available at: 
http://impact.ref.ac.uk/CaseStudies/ (last accessed 22/08/2017). 
The searchable database contains 6,637 studies. The template did not require any information to be 
returned around the use of animals under the Animals (Scientific Procedures) Act 1986 (A(SP)A). The first 
stage of research was to identify these studies. The database was interrogated for species covered under 
A(SP)A, using searches to identify case studies reporting on the use of birds, fish, amphibians, mammals, 
primates and farm animals and individual species including mice, rats, rabbits, guinea pigs, hamsters, 
dogs, cats, horse, mini-pigs, macaques, marmosets, tamarins and cephalopods. 
Given certain species names also appeared in the text as personal or institutional names, or in other 
descriptions of research, the searches were limited to submissions to Main Panel A, which includes units 
of assessments for: 
• clinical medicine 
• public health, health services and primary care 
• allied health professions, dentistry, nursing and pharmacy 
• psychology, psychiatry and neuroscience 
• biological sciences 
• agriculture, veterinary and food science 
Submissions to Panel A represented 24% of all case studies. This generated a dataset of 362 studies to 
consider. The selection was further reduced through manually checking to exclude research that was 
likely to have taken place outside of A(SP)A, removing many observational, veterinary, agricultural and 
overseas studies. Given the limited resources for this analysis, studies were excluded unless they were 
clearly covered by A(SP)A. The final set of 134 studies was summarised in a spreadsheet incorporating 
information on higher education institution, unit of assessment, named researchers, case study title, 
species used, type and routes to impact. 
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There are limitations in this use of retrospective REF data to inform the prospective evaluation of benefits. 
The assessment exercise only covers higher education institutions. Some studies were redacted from 
the searchable dataset: 296 were wholly redacted and a further 428 case studies were partially redacted. 
Studies involving research on animals may have been held back for national, institutional, or personal 
security reasons. 
The REF2014 case studies were selected by institutions based on projects best able to fulfil the reporting 
requirements and assessment criteria for measuring research impact. The dataset is thus self-selected 
from the portfolio of ongoing research at any institution. 
The grades awarded to individual impact case studies are not published, so assessments of quality are 
extrapolated from institutional evaluations. A proxy of quality for the case study was constructed by using 
the percentage of impact rated as over 3* for the submission of that institution to the relevant unit of 
assessment (see, for example, the impact profile for Unit of Assessment 1: http://results.ref.ac.uk/Results/
ByUoa/1/Impact, last accessed 22/08/2017).
The most significant challenge for this review is that the impact case studies focus on explaining the 
nature of research impact, rather than detailing underpinning research. Many studies report limited details 
of the procedures on animals. Some case studies provide information on species, disease model, location 
of research, funding and timescale in development; but in a few studies, there was only reference to a 
prior ‘animal model’. Further information is available via original research articles, but even here reporting 
is often partial, with a lack of published information on the animals, location and procedures used in 
research making it difficult to evaluate whether the original work was regulated under A(SP)A. Given these 
limitations this analysis focused on a qualitative, rather than quantitative, description of REF2014 impact 
case studies. More resources, including text mining techniques, would allow a fuller numerical description 
of these data in future. A recommendation for the future REF is that animal research data should be more 
fully recorded. 
For this research, the REF case studies were then organised into six categories, identifying indicative 
pathways to impact. These are described in the main text (see Section 4.3.4). Case studies within the six 
categories were sampled to extract information about the processes involved in generating impact from 
animal studies, which may aid the prospective evaluation of benefits. Sampling was both: 
• random – including a selection within each category 
•  purposeful – in sampling case studies with the most and least confident assessments of 
impact quality and studies involving animals in severe procedures, for which high benefits 
would be expected to achieve a positive harm-benefit analysis 
The search of impact case studies includes the ability to ‘view similar case studies’, which was used to 
inform both the categorisation of case studies and the assessment of different the pathways to impact.



